Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases

Giovanni Palermo, Sonia Mazzucchi, Alessandra Della Vecchia, Gabriele Siciliano, Ubaldo Bonuccelli, Carole Azuar, Roberto Ceravolo, Simone Lista, Harald Hampel, Filippo Baldacci

► To cite this version:

Giovanni Palermo, Sonia Mazzucchi, Alessandra Della Vecchia, Gabriele Siciliano, Ubaldo Bonuccelli, et al.. Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. *Molecular Neurobiology*, 2020, 57 (11), pp.4667-4691. 10.1007/s12035-020-02035-9 . hal-03385896

HAL Id: hal-03385896

<https://hal.sorbonne-universite.fr/hal-03385896>

Submitted on 19 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Dear Author

Here are the proofs of your article.

- You can submit your corrections **online** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- Please return your proof together with the permission to publish confirmation.
- For **fax** submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the journal title, article number, and your name when sending your response via e-mail, fax or regular mail.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.

Please note

Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI.

Further changes are, therefore, not possible.

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL:

<http://dx.doi.org/10.1007/s12035-020-02035-9>

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information, go to:

<http://www.springerlink.com>.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us, if you would like to have these documents returned.

The **printed version** will follow in a forthcoming issue.

32	Author	Family Name	Vecchia
33		Particle	
34		Given Name	Alessandra Della
35		Suffix	
36		Organization	University of Pisa
37		Division	Department of Clinical and Experimental Medicine
38		Address	Pisa, Italy
39		e-mail	
40		Family Name	Siciliano
41		Particle	
42		Given Name	Gabriele
43		Suffix	
44		Organization	University of Pisa
45	Author	Division	Department of Clinical and Experimental Medicine
46		Address	Pisa, Italy
47		e-mail	
48		Family Name	Bonuccelli
49		Particle	
50		Given Name	Ubaldo
51		Suffix	
52		Organization	University of Pisa
53	Author	Division	Department of Clinical and Experimental Medicine
54		Address	Pisa, Italy
55		e-mail	
56		Family Name	Azuar
57		Particle	
58		Given Name	Carole
59		Suffix	
60		Organization	AP-HP - Hôpital Pitié-Salpêtrière
61	Author	Division	Centre National de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie
62		Address	Paris, France
63		Organization	Institut du Cerveau et de la Moelle épinière (ICM)
64		Division	FrontLab
65		Address	Paris, France
66		e-mail	
67	Author	Family Name	Ceravolo
68		Particle	

69		Given Name	Roberto
70		Suffix	
71		Organization	University of Pisa
72		Division	Department of Clinical and Experimental Medicine
73		Address	Pisa, Italy
74		e-mail	
75		Family Name	Lista
76		Particle	
77		Given Name	Simone
78		Suffix	
79		Organization	Sorbonne University
80		Division	GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital
81	Author	Address	Boulevard de l'hôpital, Paris, France
82		Organization	Brain & Spine Institute (ICM)
83		Division	INSERM U 1127, CNRS UMR 7225
84		Address	Boulevard de l'hôpital, Paris, France
85		Organization	Pitié-Salpêtrière Hospital
86		Division	Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A)
87		Address	Paris, France
88		e-mail	
89		Family Name	Hampel
90		Particle	
91		Given Name	Harald
92		Suffix	
93	Author	Organization	Institut du Cerveau et de la Moelle épinière (ICM)
94		Division	FrontLab
95		Address	Paris, France
96		e-mail	
97		Received	10 May 2020
98	Schedule	Revised	
99		Accepted	22 July 2020
100	Abstract	One of the most pressing challenges in the clinical research of neurodegenerative diseases (NDDs) is the validation and standardization of pathophysiological biomarkers for different contexts of use (CoUs), such as early detection, diagnosis, prognosis, and prediction of treatment response. Neurofilament light chain (NFL) concentration is a particularly promising candidate, an indicator of axonal degeneration, which can be analyzed in peripheral blood with advanced ultrasensitive methods. Serum/plasma NFL	

concentration is closely correlated with cerebrospinal fluid NFL and directly reflects neurodegeneration within the central nervous system. Here, we provide an update on the feasible CoU of blood NFL in NDDs and translate recent findings to potentially valuable clinical practice applications. As NFL is not a disease-specific biomarker, however, blood NFL is an easily accessible biomarker with promising different clinical applications for several NDDs: (1) early detection and diagnosis (i.e., amyotrophic lateral sclerosis, Creutzfeldt–Jakob disease, atypical parkinsonisms, sporadic late-onset ataxias), (2) prognosis (Huntington’s disease and Parkinson’s disease), and (3) prediction of time to symptom onset (presymptomatic mutation carriers in genetic Alzheimer’s disease and spinocerebellar ataxia type 3).

101	Keywords separated by ' - '	Alzheimer’s disease - Amyotrophic lateral sclerosis - Biomarkers - Creutzfeldt–Jakob disease - NFL - Parkinsonian syndromes
102	Foot note information	Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases

Giovanni Palermo¹ · Sonia Mazzucchi¹ · Alessandra Della Vecchia¹ · Gabriele Siciliano¹ · Ubaldo Bonuccelli¹ · Carole Azuar^{2,3} · Roberto Ceravolo¹ · Simone Lista^{4,5,6} · Harald Hampel³ · Filippo Baldacci^{1,3}

Received: 10 May 2020 / Accepted: 22 July 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

One of the most pressing challenges in the clinical research of neurodegenerative diseases (NDDs) is the validation and standardization of pathophysiological biomarkers for different contexts of use (CoUs), such as early detection, diagnosis, prognosis, and prediction of treatment response. Neurofilament light chain (NFL) concentration is a particularly promising candidate, an indicator of axonal degeneration, which can be analyzed in peripheral blood with advanced ultrasensitive methods. Serum/plasma NFL concentration is closely correlated with cerebrospinal fluid NFL and directly reflects neurodegeneration within the central nervous system. Here, we provide an update on the feasible CoU of blood NFL in NDDs and translate recent findings to potentially valuable clinical practice applications. As NFL is not a disease-specific biomarker, however, blood NFL is an easily accessible biomarker with promising different clinical applications for several NDDs: (1) early detection and diagnosis (i.e., amyotrophic lateral sclerosis, Creutzfeldt–Jakob disease, atypical parkinsonisms, sporadic late-onset ataxias), (2) prognosis (Huntington’s disease and Parkinson’s disease), and (3) prediction of time to symptom onset (presymptomatic mutation carriers in genetic Alzheimer’s disease and spinocerebellar ataxia type 3).

Keywords Alzheimer’s disease · Amyotrophic lateral sclerosis · Biomarkers · Creutzfeldt–Jakob disease · NFL · Parkinsonian syndromes

Introduction

Neurodegenerative diseases (NDDs) are currently considered as a continuum of disorders with common pathophysiological

mechanisms, including misfolded protein deposition, neuronal synaptic disruption, axonal degeneration, neuroinflammation, and oxidative stress [1–3]. Therefore, the greatest current challenge in the field of NDDs is to provide biomarkers for the pathological mechanisms underlying each clinical picture [4], in order to improve the diagnostic and prognostic stratification of the patients and to allow early diagnosis and disease monitoring as well as to test treatment efficacy.

Within this multifaceted *scenario*, neurofilament light chain (NFL) is, at the present, the most promising candidate biomarker for an early identification of a general neurodegenerative process able to support disease diagnosis, prognosis, and progression, as well as monitoring an eventual disease-modifying treatment [5–7]. It is a component of neurofilaments (NFs) that, together with glial filaments, are the main types of intermediate filaments (IFs) of the nervous system [9–11]. Its physiological function is to confer mechanical stress resistance by preserving the characteristic cellular shape, intracellular traffic regulation between axons and dendrites, and, indirectly, nerve conduction speed modulation maintaining axon diameter [11]. Recent research suggests that they are also important for normal synaptic function [12]. Axonal dysfunction and degeneration are

✉ Filippo Baldacci
filippo.baldacci@unipi.it

¹ Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
² Centre National de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France
³ FrontLab, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
⁴ GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Sorbonne University, Boulevard de l’hôpital, Paris, France
⁵ INSERM U 1127, CNRS UMR 7225, Brain & Spine Institute (ICM), Boulevard de l’hôpital, Paris, France
⁶ Department of Neurology, Institute of Memory and Alzheimer’s Disease (IM2A), Pitié-Salpêtrière Hospital, Paris, France

important steps in NDD pathogenesis, occurring long before neuronal cell death and often preceding detectable deposition of misfolded proteins [8]. During these processes, NFL is released into the extracellular space and, consequently, into body fluids, such as the cerebrospinal fluid (CSF) and blood.

Broadly speaking, mounting data reported increased CSF NFL levels in NDDs [5, 6, 13]. In the mid-1990s, through the first enzyme-linked immunosorbent assay (ELISA) developed for NFL, Rosengren and colleagues [14] demonstrated that CSF NFL concentration was increased in amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and vascular cognitive impairment (VCI). Although with different magnitudes, further studies revealed that CSF NFL increased also in other several NDDs, such as frontotemporal dementia (FTD) [15, 16], Parkinson's disease (PD) and atypical parkinsonisms (APs) [17, 18], Huntington's disease (HD) [19], mild cognitive impairment (MCI) [20, 21], and Creutzfeldt–Jakob disease (CJD) [22, 23], as well as in non-primary neurodegenerative disorders, such as multiple sclerosis (MS) [24], neuroinfectious conditions [25], traumatic brain injury [26], acute stroke [27], and cerebrovascular diseases [28]. Moreover, in NDDs, CSF NFL levels showed to correlate with poorer cognition, short survival times, brain atrophy, and disease severity and progression [29–31], supporting the notion that it could be useful not only as a diagnostic biomarker but also as a prognostic and progression biomarker [32]. As a result, it has been proposed as a dynamic biomarker for axonal degeneration [5, 6, 13] with the potential capacity to monitor treatment effectiveness [10, 33].

In the last few years, the interest in NFL research shifted toward blood. An ideal biomarker should be easily measurable, accurate, quantitative, reproducible, and employable to exactly categorize the population in line with a certain disease [34, 35]. To this end, blood-based biomarkers would have significant advantages in time efficiency and cost efficiency compared to CSF and neuroimaging [36, 37]. Moreover, they would offer potential applications at the population level as screening tools in primary care, as well as for longitudinal evaluations with repeated sampling during follow-up. It is not surprising that brain pathophysiological processes are reflected into the periphery. However, CSF proteins partially enters the blood flow, are subsequently diluted in a greater volume compared with CSF, and go through biochemical interactions with a large amount of plasma proteins. They are also cleared by blood cells and metabolized by other tissues. Finally, these processes overall hamper their measurement in plasma or serum using traditional techniques. Nevertheless, in the past few years, the development of analytical tools for ultrasensitive quantification—the immunomagnetic reduction (IMR) and the single molecule array (Simoa) techniques—by allowing an efficient measurement of NFL in blood [38], charted a tight correlation between CSF and blood NFL in different NDDs [39]. Therefore, blood NFL was suggested

as a proxy of any neurodegenerative process, paving the way to its use in clinical practice as a reliable risk biomarker for neurodegeneration [40, 41]. Nonetheless, its potential application in real life remains unclear [42].

Biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biologic and pathogenic processes, or pharmacologic responses to a therapeutic intervention” [43]. From a clinical perspective, a biomarker can be also classified in further categories with some practical and conceptual overlaps: (1) antecedent biomarkers identifying a risk of disease development (*risk biomarkers*), (2) early biomarkers screening a subclinical condition (*screening biomarkers*), (3) biomarkers specifically recognizing a full-blown clinical picture (*diagnostic biomarkers*), (4) biomarkers categorizing disease severity (*staging biomarkers*), (5) biomarkers predicting future disease course (*prognostic biomarkers*), and (6) biomarkers predicting treatment response (*predicting or monitoring biomarkers*) [44]. Accordingly, it is crucial to define the context of use of a certain biomarker (primary care screening, diagnostic, risk of progression, disease monitoring, stratification for clinical trials, and pharmacodynamic or treatment response monitoring).

This review will attempt to summarize the current literature on blood (plasma or serum) NFL in NDDs, trying to translate research data in practical considerations, focusing on the context of use of blood NFL as a biomarker in the framework of the NDDs (Table 1).

Literature Research Methods

We conducted a systematic review of the literature until February 2020, using the key terms “NFL,” “neurofilament light chain,” and “neurofilament” to interrogate the PubMed database for articles published in English evaluating blood NFL concentrations (serum and plasma) in NDDs. Overall, we identified 38 studies. The use of internationally accepted clinical diagnostic criteria for each NDD, in particular AD [45–49], ALS [50–52], dementia with Lewy bodies (DLB) [53–55], FTD [56–58], PD [59–61], AP [62–65], and sporadic Creutzfeldt–Jakob disease (sCJD) [66, 67], has been checked out for any single study. The diagnostic performance of blood NFL concentrations to correctly allocate the participants to the different diagnostic groups was considered as follows: “excellent” (area under the ROC curve (AUROC) 0.90–1.00), “good” (AUROC 0.80–0.89), “fair” (AUROC 0.70–0.79), “poor” (AUROC 0.60–0.69), or “fail” (i.e., no discriminatory capacity) (AUROC 0.50–0.59) [68].

AD

AD is the most common form of dementia in the elderly, accounting for 50–70% of prevalent neurodegenerative

Table 1 Overview on the possible context of use of blood NFL as a biomarker in NDDs

		Diagnostic value			Prognostic value	Monitoring treatment
		Preclinical phase	Prodromal phase	Full-blown picture		
	AD	±	+	+	+	±
	PD	±	±	+	+	±
	Atypical parkinsonisms (4R tauopathies)	±	±	+	+	±
	DLB	±	±	±	±	±
	FTD	–	±	+	–	±
	ALS	±	±	+	±	±
	CJD	±	+	+	–	±
	HD	–	–	–	+	±
	SMA	–	–	–	±	+
	Sporadic late-onset ataxias	±	±	±	+	±
	NDDs as a whole	±	+	+	+	±

Plus sign (+), potential use, supportive data are available; plus-minus sign (±), unknown; negative sign, negative evidences are available

AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CJD Creutzfeldt–Jakob disease, DLB dementia with Lewy body, FTD frontotemporal dementia, HD Huntington’s disease, NDD neurodegenerative diseases, PD Parkinson’s disease, SMA spinal muscular atrophy

dementia cases with an enormous health and economic impact [69]. The scientific and clinical research is nowadays shifting from dementia to the prodromal or even preclinical phases of AD to find effective therapeutic interventions that can delay or halt neurodegenerative progression [70, 71].

Biomarkers hold promise for improving early diagnosis in AD and establishing a tailored approach. The use of specific surrogate biomarkers (neuroimaging, blood [plasma/serum], and CSF) of AD pathology has been included in revised diagnostic criteria to distinguish AD from other forms of dementia since its early disease stages. However, postmortem studies demonstrate a high degree of neuropathologic heterogeneity in patients who received a clinical diagnosis of AD [72]. The pathogenesis of AD involves interacting pathophysiological cascades in which the deposition of amyloid plaques (Aβ) and the formation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein would represent only the core events. The recently established “A/T/N” scheme proposes three binary biomarker categories which reflect AD pathophysiology, where “A” refers to Aβ pathology, “T” to tau pathology, and N to neurodegeneration [73, 74]. However, emerging evidence stresses the existence of additional molecular pathophysiological pathways, such as synaptic dysfunction and degeneration, innate immune response and neuroinflammation, vascular and cell membrane dysregulation, brain metabolic dysfunction, and axonal disruption [75]. The latter is prominent in AD, and it is more closely related to cognitive decline than Aβ pathology [76], thus leading to propose CSF NFL as a non-specific biomarker to detect early AD pathophysiological alterations [77]. In addition, an increased release of NFL molecules is a consequence of aging that contributes to an axonal degeneration due to subclinical cerebrovascular changes and neuronal atrophy [78]. In this regard, a recent

prospective community-based study enrolling a cohort of cognitively intact subjects reported high variability of serum NFL levels above 60 years [79].

Several studies showed that CSF NFL levels are elevated in AD patients when compared with healthy controls (HCs) and higher NFL concentration is predictive of a rapid disease progression along core biomarkers of AD pathology [21]. Peripheral serum or plasma NFL strongly correlated with CSF NFL concentration, suggesting that it reflects the same pathological process [80]. In general, we found that the levels of NFL are higher in serum than in plasma, but the majority of studies used plasma to quantify NFL.

NFL as Diagnostic Biomarker

Current evidence revealed that plasma NFL allows to discriminate AD patients from HC subjects with a good/excellent diagnostic accuracy [77, 81] (Table 2). In addition, plasma NFL levels showed to be higher in the AD dementia group than in the MCI group and in Aβ-positive MCI patients than HC [77]. More recently, this finding has been replicated in a larger study in the Dominantly Inherited Alzheimer Network (DIAN) [82]. Other studies reported higher plasma/serum NFL levels in AD and MCI patients compared with controls [76, 83, 84], but with conflicting results about the differences between MCI and cognitively normal individuals. A recent meta-analysis by Wang and colleagues [85] confirmed these findings, supporting a possible contribute of plasma NFL in the AD diagnostic workup. Moreover, plasma NFL levels could also reflect NFT pathology (as determined by NFL immunostaining) and neurodegeneration at post-mortem evaluation [76].

Table 2 The utility of NFL in the diagnostic and progression evaluation of neurodegenerative diseases

	First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.1	AD				
t2.2	Preische, 2019 (longitudinal study)	HC (AD mutation non-carriers) <i>n</i> = 162	AD presymptomatic mutation carriers, <i>n</i> = 243	<ul style="list-style-type: none">- Rate of change of serum NFL in differentiating non-mutation carriers vs presymptomatic mutation carriers, AUROC = 0.7- Non-mutation carriers vs symptomatic non-mutation carriers, AUROC = 0.89- Baseline serum NFL value in differentiating non-mutation carriers vs presymptomatic mutation carriers, AUROC = 0.49 (at the cutoff value of 37.4 pg/mL)- Non-mutation carriers vs symptomatic non-mutation carriers, AUROC = 0.85 (at the cutoff value of 27.9 pg/mL)- Plasma NFL in differentiating patients vs HC, AUROC = 0.85 (95% CI 0.772–0.934), unadjusted for other variables- AD vs HC, AUROC = 0.92 (95% CI 0.869–0.970), adjusted for age- At the cutoff maximizing Youden index, 25.7 pg/mL, the unconditional accuracy was 0.82	<ul style="list-style-type: none">- Mutation carriers were subdivided into 3 groups: presymptomatic mutation carriers (individuals who scored 0 on the CDR scale across all visits), converters (CDR = 0 at baseline and CDR > 0 at subsequent visits), and symptomatic mutation carriers (CDR > 0 across all visits)
t2.3	Lewczuk, 2018 (cross-sectional study)	HC = 41	MCI-AD = 25 ADD = 33 AD = 58	<ul style="list-style-type: none">- Plasma NFL in differentiating patients vs HC, AUROC = 0.85 (95% CI 0.772–0.934), unadjusted for other variables- AD vs HC, AUROC = 0.92 (95% CI 0.869–0.970), adjusted for age- At the cutoff maximizing Youden index, 25.7 pg/mL, the unconditional accuracy was 0.82	<ul style="list-style-type: none">- MCI-AD were AD patients at the stage of MCI.- ADD were AD patients at the stage of early dementia.- AD included MCI-AD + AD patients
t2.4	Mattsson, 2017 (longitudinal study)	HC = 193	AD = 180 MCI = 197 pMCI = 109 sMCI = 65	<ul style="list-style-type: none">- Plasma NFL in differentiating AD vs CNC, AUROC = 0.87 (correcting for age, sex, educational level, and <i>APOE</i> ε4 genotype). When only correcting for age, sex, and educational level, the AUROC was reduced to 0.79	<ul style="list-style-type: none">- Patients were recruited from the ADNI cohort.- MCI patients were divided into stable MCI (sMCI, with no progression to dementia during ≥ 2-year follow-up) and progressive MCI (pMCI, with conversion to dementia)
t2.5	FTD				
t2.6	van der Ende, 2019 (longitudinal study)	Non-carriers of a mutation in GRN, C9orf72, or MAPT = 127	Presymptomatic carriers of a mutation in GRN, C9orf72, or MAPT = 149 FTD (symptomatic carriers of a mutation in GRN, C9orf72, or MAPT) = 59	<ul style="list-style-type: none">- Serum NFL in differentiating symptomatic mutation carriers vs presymptomatic mutation carriers, AUROC = 0.93 (95% CI 0.90–0.97), at the cutoff concentration of 17 pg/mL- Symptomatic mutation carriers vs non-mutation carriers, AUROC = 0.95 (95% CI 0.92–0.98), at the cutoff concentration of 17 pg/mL- Baseline serum NFL converters vs presymptomatic mutation carriers, AUROC = 0.93 (95% CI 0.89–0.98), at the cutoff level of 15.0 pg/mL	<ul style="list-style-type: none">- Multicenter cohort study on families with genetic FTD in Europe and Canada- At least 2 serum samples were taken with a time interval of 6 months or more.- 9 presymptomatic carriers became symptomatic during follow-up (converters).- Presymptomatic carriers or non-carrier mutations were healthy relatives of first degree at risk of FTD
t2.7	Katisko, 2019 (longitudinal study)	FTD = 91 (bvFTD = 66; nvPPA = 16; svPPA = 4; FTD-MND = 5) PPD = 34		<ul style="list-style-type: none">- Serum NFL in differentiating FTD vs PPD, AUROC = 0.85 (95% CI 0.776–0.923), at the cutoff level of 19.9 pg/mL	<ul style="list-style-type: none">- The PPD group included patients with a severe late-onset psychiatric disorder (psychotic, mood disorders, or both).

t2.10 **Table 2** (continued)

First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.10 Al Shweiki, 2019 (cross-sectional study)	HC = 27	bvFTD = 20 Schizophrenia = 11 Depression = 28 Bipolar disorder = 11	<ul style="list-style-type: none"> - bvFTD vs PPD, AUROC = 0.82 (95% CI 0.732–0.908), at the cutoff level of 19.9 pg/mL - Serum NFL in differentiating bvFTD vs HC, AUROC = 0.94 (95% CI 0.87–0.99) - bvFTD vs depression, AUROC = 0.89 (95% CI 0.8–0.98), at a cutoff level above 35.7 pg/mL - bvFTD vs bipolar disorder, AUROC = 0.94 (95% CI 0.81–1.01), at a cutoff level > 26.5 pg/mL - bvFTD vs schizophrenia, AUROC = 0.9 (95% CI 0.77–1.03), at a cutoff level > 17.7 pg/mL - Serum NFL in differentiating bvFTD vs AD, AUROC = 0.67 - bvFTD vs MCI, AUROC = 0.9 (95% CI 0.84–0.97) - bvFTD vs HC, AUROC = 0.85 (95% CI 0.72–0.97) - bvFTD vs AD subgroups selected based on CSF Aβ42 levels, AUROC = 0.79, at a cutoff value of 33 pg/mL - bvFTD vs AD subgroups selected based on both CSF Aβ42 and tau/p-tau levels, AUROC = 0.77, at a cutoff value of 34.3 pg/mL 	<ul style="list-style-type: none"> - In the FTLD group, 26 patients had a definite diagnosis due to the C9orf72 repeat expansion - 20 bvFTD consisting of 9 possible bvFTD, 5 probable bvFTD, and 6 genetic bvFTD (4 due to C9orf72 mutations, 2 MAPT mutations) - Serum NFL levels did not differ between psychiatric and control patients - Genetic screening of 67 patients with bvFTD revealed 7 carriers for C9orf72 repeat expansion. - Analysis of MAPT and GRN in 18 patients revealed 1 carrier of the MAPT mutation and 1 carrier of the GRN mutation
t2.11 Steinacker, 2018 (longitudinal study)	HC = 15	bvFTD = 74 AD = 26 (excluding patients with normal Aβ42) AD = 11 (without the typical AD CSF biomarker pattern) MCI = 17 Subgroups were defined on the basis of both CSF Aβ42 and tau levels: - 30 bvFTD (excluding patients with decreased Aβ42) - 31 bvFTD (excluding patients with decreased Aβ42 and increased tau or p-tau)	<ul style="list-style-type: none"> - Serum NFL in differentiating FTD vs HC, AUROC = 0.81 (95% CI 0.72–0.91) at an optimal cutoff value > 36 pg/mL - ALS vs HC, AUROC = 0.99 (95% CI 0.98–1.00) - Serum NFL in differentiating FTD vs HC, AUROC = 0.97 (95% CI 0.93–1.00) - FTD vs presymptomatic carriers, AUROC = 0.93 (95% CI 0.87–0.98), at the cutoff level of 18.0 pg/mL 	<ul style="list-style-type: none"> - Patients with PPA met only clinical diagnostic criteria without knowledge of fluid biomarker concentration - Participants were recruited as part of GENFI or ascertained before participation in GENFI. - 4 subjects became symptomatic during follow-up (converters)
t2.12 Steinacker, 2017 (longitudinal study)	HC = 35	PPA = 99 (nfvPPA = 40, svPPA = 38, lvPPA = 21)		
t2.13 Wilke, 2016 (cross-sectional study)	HC = 46	FTD = 41 ALS = 25		
t2.14 Meeter, 2016 (longitudinal study)	HC = 71	FTD (caused by a pathogenic mutation in GRN, MAPT, or C9orf72) = 101		

Table 2 (continued)

First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.15 ALS		Presymptomatic carriers of a pathogenic mutation = 62	<ul style="list-style-type: none"> - Presymptomatic carriers vs HC, AUROC = 0.63 (95% CI 0.51–0.75), at the cutoff level of 8.3 pg/mL - Serum NFL was also associated with survival (HR in the higher tertile 3.10, 95% CI 1.09–8.76) 	
t2.16 Thouvenot, 2019 (longitudinal study)	HC = 21	ALS = 198	<ul style="list-style-type: none"> - Serum NFL > 15.0 pg/mL in discriminating ALS vs HC, AUROC = 0.99 (95% CI 0.972–0.999) - Patients with serum NFL levels ≥ 71.2 pg/mL had a higher risk of death (HR 4.7, 95% CI 3.0–7.4) - A cutoff NFL level of 49 pg/mL in differentiating ALS vs non-neurodegenerative controls, AUROC = 0.97 (95% CI 0.95 to 0.991) - A cutoff value of 62 pg/mL in differentiating ALS vs disease controls, AUROC = 0.87 (95% CI 0.81 to 0.935) - A cutoff value of 62 pg/mL in discriminating ALS vs all other categories considered together, AUROC = 0.88 (95% CI 0.849 to 0.926) - Patients with serum NFL above the median (125 pg/mL) had a shorter survival than patients with NFL ≤ 125 pg/mL, with an HR of 2.39 (95% CI 1.236 to 4.63) 	<ul style="list-style-type: none"> - Patients were prospectively followed up to 18.5 months - Disease controls included in the differential diagnosis of ALS
t2.17 Verde, 2019 (longitudinal study)	Non-neurodegenerative controls = 50	ALS = 124 Disease controls = 44 FTD = 20 AD = 20 PD = 19 CJD = 6	<ul style="list-style-type: none"> - Serum NFL in differentiating ALS vs ALS mimic, AUROC = 0.85 (95% CI 0.79–0.90), at an optimal cutoff value of 93 pg/mL - ALS fast progressor vs ALS slow progressors, AUROC = 0.87 (95% CI 0.76–0.94), at an optimal cutoff value of 159 pg/mL - ALS vs GBS + CIDP, AUROC = 0.58 (95% CI 0.51–0.64), at an optimal cutoff value of 139 pg/mL - ALS vs HSP, AUROC = 0.84 (95% CI 0.78–0.90), at an optimal cutoff value of 55 pg/mL - ALS vs PLS, AUROC = 0.89 (95% CI 0.83–0.93), at an optimal cutoff value of 88 pg/mL - ALS vs PMA, AUROC = 0.71 (95% CI 0.63–0.78), at an optimal cutoff value of 86 pg/mL - ALS patients with serum NFL in the upper tertile had a HR = 5.34 (95% CI 1.39–20.56) vs patients with serum NFL in the low tertile. 	<ul style="list-style-type: none"> - A subset of 16 ALS repeated serum sample showing a relative stability of NFL concentrations over time
t2.18 Gille, 2018 (longitudinal study)		ALS = 149 (C9orf72 = 15, FTD = 15, PLS = 11, PMA = 6) ALS mimic = 19 Disease controls = 82 (GBS, CIDP, HSP)		

t2.19 **Table 2** (continued)

First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.19 Feneberg, 2018 (cross-sectional study)		ALS onset ≤ 6 months = 54 ALS onset > 6 months = 135 Other MNDs (PLS, SMA, Kennedy disease) = 21 ALS mimics = 27 Neurologic disease controls = 60	<ul style="list-style-type: none">- ALS patients with serum NFL in the mid-tertile had a HR = 4.47 (95% CI 1.08–18.63) vs patients with serum NFL in the low tertile- Serum NFL in differentiating early ALS vs neurologic disease controls, AUROC = 0.92 (95% CI 0.85–0.99, cutoff = 128 pg/mL)- Early ALS vs MND mimics, AUROC = 0.99 (95% CI 0.97–1, cutoff = 97 pg/mL)- Late ALS vs neurologic disease controls, AUROC = 0.9 (95% CI 0.83–0.97, cutoff = 116 pg/mL)- Late ALS vs MND mimics, AUROC = 0.97 (95% CI 0.94–1, cutoff = 95 pg/mL) High NFL concentrations were associated with shorter survival (at least a 6-month follow-up) [numbers are not reported]	<ul style="list-style-type: none">- A minimum 3-month follow-up- Serum NFL concentrations were not significantly different between early and later symptomatic phases
t2.20 Steinacker, 2016 (longitudinal study)	HC = 28	ALS = 125		<ul style="list-style-type: none">- Patients were subgrouped according to the progression rate at first examination into slow, intermediate, and fast progressors.- Blood NFL measures were taken every 6 months up to 3 years of follow-up and were stable over time
t2.21 Lu, 2015 (longitudinal study)	HC = 78 (London cohort = 42; Oxford cohort = 36)	ALS = 167 (London cohort = 103; Oxford cohort = 64)	<ul style="list-style-type: none">- Serum NFL in differentiating ALS vs HC, AUROC = 0.86, at a cutoff level of 36 pg/mL (Oxford cohort)- Plasma NFL in differentiating ALS vs HC, AUROC = 0.87, at a cutoff level of 36.2 pg/mL (London cohort)- Patients with serum NFL (Oxford cohort) in the highest tertile had a HR = 6.05 (95% CI 1.68–21.87).- Patients with plasma NFL (London cohort) in the highest tertile had a HR = 3.78 (95% CI 1.68–8.50).- Patients with serum NFL (Oxford cohort) in the middle tertile had a HR = 2.68 (95% CI 0.87–8.27).- Patients with plasma NFL (London cohort) in the middle tertile had a HR = 1.91 (95% CI 0.86–4.23).- Patients with combined blood NFL in the highest tertile had a HR = 3.82 (95% CI 1.98–7.39).- Patients with combined blood NFL in the middle tertile had a HR = 2.08 (95% CI 1.09–3.97) Serum NFL in differentiating ALS vs HC, with sensitivity of 91.3% and specificity of 91% at a cutoff level of 26.6 pg/mL	<ul style="list-style-type: none">- Multicenter study (2 cohorts)- Authors also conducted analyses of the 2 cohorts combined, using the corresponding NFL data (serum or plasma) from each cohort, using cohort-specific tertile cutoff levels, and adjusting Cox regression and Kaplan–Meier survival analyses by center
t2.22 Gaiotino 2013 (cross-sectional study)	HC = 67	ALS = 46 AD = 20 GBS = 19		<ul style="list-style-type: none">- Neurological control patients consisted of patients suffered from tension-type headache (n = 21), lower back pain (n = 7), psychiatric

Table 2 (continued)

Springer

First author (type of study)	Controls	Patients	Neurological control patients = 68	Diagnostic/prognostic value of blood NFL	Notes
t2.23 Parkinsonian syndromes and degenerative ataxias					
t2.24 Oosterveld, 2020 (cross-sectional study)	HC = 52	PD = 139	Neurological control patients = 68	Serum NFL in differentiating PD vs HC, AUROC = 0.64 (95% CI 0.55–0.73), at the cutoff value of 15.6 pg/mL	disorders ($n = 26$), or miscellaneous non-specific symptoms for which no neurological explanation could be found ($n = 14$)
t2.25 Ng, 2020 (longitudinal study)	HC = 50	PD = 149 (76 PD patients, 30 TD and 46 PiGD, had plasma NFL measured at the 2-year mark)		<ul style="list-style-type: none"> - Baseline plasma NFL in differentiating PD vs HC, AUROC = 0.83 (95% CI 0.77–0.89) - At year 2, plasma NFL in discriminating TD subtype vs PiGD subtype, AUROC = 0.65 (95% CI 0.53–0.77) 	<ul style="list-style-type: none"> - The inclusion of serum NFL in a panel of CSF biomarkers (phosphorylated α-synuclein/total α-synuclein ratio and oligomeric α-synuclein/total α-synuclein ratio) yielded a sensitivity of 91% and a specificity of 81% (AUC 0.90, 95% CI 0.83–0.97) - Participants were included in the Early Parkinson's Disease Longitudinal Singapore Study which is an ongoing prospective cohort study analyzing the progression of early PD over a follow-up period of 5 years. - PD patients were classified into motor subtypes of "tremor dominant" (TD), "postural instability and gait disorders" (PiGD), or "indeterminate" based on MDS-UPDRS part II and III components
t2.26 Marques, 2019 (cross-sectional study)	HC = 53	PD = 55 AP (MSA = 22, PSP = 7) = 29		<ul style="list-style-type: none"> - Serum NFL in differentiating AP vs PD, AUROC = 0.91 (95% CI 0.83–0.98), at the cutoff value of 14.8 ng/L - AP vs HC, AUROC = 0.88 (95% CI 0.80–0.96), at the cutoff value of 13.6 ng/L 	<ul style="list-style-type: none"> - Patients were recruited when the clinical diagnosis was still uncertain; definite clinical diagnosis was established after 3 years of follow-up and updated again after a maximum of 12 years of follow-up data - Participants in cohort B were classified into 3 subgroups according to the SARA scores: 26 preclinical SCA-3 individuals, 46 stage 1 SCA-3 patients, and 44 stage 2 SCA-3 patients
t2.27 Li, 2019 (cross-sectional study)	HC = 100 consisting of 2 cohorts: - Cohort A = 9 - Cohort B = 91	Manifest SCA-3 = 107, consisting of 2 cohorts: - Cohort A = 17 - Cohort B = 90 Preclinical SCA-3 = 26 (all included in the cohort B)		<ul style="list-style-type: none"> - Serum NFL in differentiating manifest SCA-3 vs HC, AUROC = 0.98 (95% CI 0.96–1.00), at the cutoff value of 20 pg/mL - Preclinical SCA-3 vs HC, AUROC = 0.83 (95% CI 0.72–0.95), at the cutoff value of 10 pg/mL 	<ul style="list-style-type: none"> - PD patients with baseline NFL levels > 21.84 pg/mL were at higher risk of motor symptom progression. - PD patients with baseline NFL levels > 18.34 pg/mL were at higher risk of cognitive decline
t2.28 Lin, 2019 (longitudinal study)	HC = 40	PD = 116 MSA = 22		<ul style="list-style-type: none"> - Plasma NFL in differentiating MSA vs PD, AUROC = 0.80, at the cutoff value of 24.06 pg/mL - PD vs HC, AUROC = 0.75, at the cutoff value of 12.34 pg/mL - Higher baseline NFL levels were associated with a higher risk of motor symptom progression (adjusted HR 1.03, 95% CI 1.01–1.07) and cognition progression (adjusted HR 1.03, 95% CI 1.01–1.05) 	

Table 2 (continued)

First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.29 t2.30 Donker Kaat, 2018 (longitudinal study)	HC = 95	PSP = 131	- Serum NFL in differentiating PSP vs HC, AUROC = 0.87 (95% CI 0.83–0.92), at the cutoff value of 38.3 pg/mL - Higher NFL levels were associated with reduced survival (adjusted HR 1.5, 95% CI 1.1–1.9)	- Diagnosis of PSP was made according to NINDS-SPSP criteria (2003–2014); 23 patients had pathological confirmation
t2.31 Wilke, 2018 (cross-sectional study)	HC = 45	c-MSA = 25 SAOA = 25 SCA = 20	- Serum NFL in differentiating c-MSA vs SAOA, AUROC = 0.74 (95% CI 0.59–0.89) - SCA vs HC, AUROC = 0.91 (95% CI 0.81–1.00)	- SCA patients consisted of SCA-1 ($n = 6$), SCA-2 ($n = 3$), SCA-3 ($n = 8$), and SCA-6 ($n = 3$)
t2.32 Hansson, 2017 (longitudinal study)	- Lund cohort HC = 53 - London cohort HC = 26	- Lund cohort PD = 171 - Lund cohort AP = 54 (MSA = 30, PSP = 19, CBD = 5) - London cohort PD = 20 - London cohort AP = 71 (MSA = 30, PSP = 29, CBD = 12) - Early-stage disease cohort PD = 53 - Early-stage disease cohort AP = 56 (MSA = 28, PSP = 22, CBD = 6)	- Blood NFL in differentiating PD vs AP, AUROC = 0.91 (95% CI 0.87–0.95) (Lund cohort) - PD vs AP, AUROC = 0.85 (95% CI 0.72–0.98) (London cohort) - PD vs AP, AUROC = 0.81 (95% CI 0.73–0.90) (early-stage disease cohort)	- The study included 2 independent prospective cohorts of PD and AP patients and HC: the Lund ($n = 278$) and London ($n = 117$) cohorts. - The third cohort consisted of PD and AP patients with a disease duration < 3 years (early-stage disease cohort, $n = 109$)
t2.33 HD				
t2.34 Byrne, 2018 (cross-sectional study)	HC = 20	HTT mutation carriers (premanifest HD = 20; manifest HD = 40) = 60	- Plasma NFL in differentiating HTT mutation carriers vs HC, AUROC = 0.91 (95% CI 0.85–0.97) - Plasma NFL in differentiating premanifest HD vs manifest HD, AUROC = 0.93 (95% CI 0.86–0.99)	- Participants were enrolled in the TRACK-HD* study. - At enrollment, participants with <i>HTT</i> CAG expansion mutations were classified as having premanifest or manifest HD based on the UHDRS-TMS.
t2.35 Byrne, 2017 (longitudinal study)	HC = 97	HTT mutation carriers (premanifest HD = 104, manifest HD = 97) = 201 They were divided into: - Early premanifest HD = 58 - Late premanifest HD = 46 - Manifest HD stage 1 = 66 - Manifest HD stage 2 = 31	Higher baseline plasma NFL levels in premanifest HD were associated with clinical disease onset during the 3-year follow-up period, adjusted HR 3.03, 95% CI 1.07–8.60	- 18 (17%) subjects with premanifest disease at baseline were newly diagnosed as having manifest HD during the 3 years of follow-up
t2.36 CJD				
t2.37 Staffaroni et al., 2019 (longitudinal study)		sCJD = 188	Higher baseline levels of plasma NFL levels were associated with shorter survival, HR 2.08 (95% CI 1.22–3.54)	Participants included patients with probable and definite (pathology-proven) sCJD with PRNP codon 129 polymorphism data available

Table 2 (continued)

First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.39 Thompson, 2018 (cross-sectional study)	HC = 24	sCJD = 45	Serum NFL in differentiating sCJD vs HC, AUROC = 1.0	- The present study included 132 autopsy cases with rapidly progressive neurological syndromes.
t2.40 Kovacs, 2017 (cross-sectional study)	HC = 18	sCJD = 65 gCJD = 21 AD = 21 Other neurological pathologies = 25	AUROC = 0.99 (95% CI 0.98–1.0) - gCJD vs HC, AUROC = 1.0 (CI 1.0–1.0) - AD vs HC, AUROC = 0.99 (95% CI 0.97–1.0) - Other neurological disorders vs HC, AUROC = 0.96 (CI 0.90–1.0)	- Cases with a wide range of neuropathological alterations, including cerebrovascular disease, inflammation (meningoencephalitis), primary age-related tauopathy, non-AD tauopathies or Lewy body pathology
t2.41 Steinacker, 2016 (cross-sectional study)	HC = 40	sCJD = 33 gCJD = 9 GSS mutation carrier = 1 Demented controls (DCo) = 20	Serum NFL in differentiating sCJD + gCJD vs HC + DCo, AUROC = 0.95	- 39 CJD diagnoses were neuropathologically verified. - Patients with other diseases included AD (n = 12), MCI (n = 4), FTD (n = 3), and NPH (n = 1)

Aβ42 amyloid β-peptide 1–42; AD Alzheimer’s disease; ADNI Alzheimer’s Disease Neuroimaging Initiative; ALS amyotrophic lateral sclerosis; AP atypical parkinsonism; APOE apolipoprotein E; AUROC area under the receiver operating curve; bvtFTD behavioral variant of frontotemporal dementia; c-MSA cerebellar variant MSA; CBD corticobasal degeneration; CDR cognitive dementia rating; CI confidential interval; CIDD chronic inflammatory demyelinating polyneuropathy; CJD Creutzfeldt–Jakob disease; CSF cerebrospinal fluid; C9ORF72 chromosome 9 open reading frame 72; DLB dementia with Lewy body; FTD frontotemporal dementia; FTD-MND frontotemporal dementia with ALS; gCJD genetic Creutzfeldt–Jakob disease; GBS Guillain-Barre syndrome; GENFI genetic FTD initiative; GSS Gerstmann–Sträussler–Scheinker disease; GRN granulin; HC healthy controls; HD Huntington’s disease; HR hazard ratio; HSP hereditary spastic paraplegia; HTT huntingtin; hPPA logopenic variant PPA; MAPT microtubule-associated protein tau; MCI mild cognitive impairment; MCI-AD MCI converters to AD; MDS-UPDRS Movement Disorder Society–Unified Parkinson’s Disease Rating Scale; MND motor neuron disease; MSA multiple system atrophy; NFL neurofilament light chain; nfvPPA non-fluent variant PPA; NINDS-SPSP National Institute of Neurological Disorders and Stroke and the Society for PSP; NPH normal-pressure hydrocephalus; PD Parkinson’s disease; PLS primary lateral sclerosis; PPA primary progressive aphasia; PMA primary muscular atrophy; PPD primary psychiatric disorders; PRNP prion protein; PSP progressive supranuclear palsy; p-tau phospho-tau; sCJD sporadic Creutzfeldt–Jakob disease; SAOA sporadic adult-onset ataxia; SARA Scale for the Assessment and Rating of Ataxia; SCA spinocerebellar ataxia; SMA spinal muscular atrophy; svPPA semantic variant PPA; UHDRS Unified Huntington’s Disease Rating Scale–Total Motor Score

*TRACK-HD is a multinational prospective observational study of HD that examines clinical and biological findings of disease progression in individuals with premanifest HD and early-stage HD

NFL as Staging and Prognostic Biomarker

Studies in AD and MCI-AD patients found a correlation between plasma NFL concentration and cognitive impairment, MRI hippocampal volume loss and brain atrophy, and cerebral ¹⁸F-FDG-PET hypometabolism [76, 81–87]. Moreover, higher plasma NFL levels predicted faster cognitive deterioration and a higher rate of brain atrophy and hypometabolism in MCI patients over time [77]. Baseline plasma and CSF NFL levels were similarly associated with short-term declines in imaging measures of neurodegeneration and with global cognitive worsening, but not with change in amyloid ligand retention on PET [35], differently from CSF t-tau concentration that critically depends on cerebral Aβ burden [88]. Instead, increased plasma NFL was related to baseline and longitudinal glucose hypometabolism, which is an unspecific neurodegeneration marker, in AD-related regions of MCI Aβ+ individuals [87].

In a longitudinal analysis of NFL plasma levels in a large cohort of subjects enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), Mattsson and colleagues [82] found increasing rates of NFL changes from preclinical AD stage to frank AD dementia through prodromal phase, suggesting NFL as a dynamic biomarker sensitive to AD disease progression. Of note, longitudinal NFL variations correlated with several baseline AD-related features (CSF biomarkers, imaging measures, and cognition) in the whole population, though with significant differences regarding clinical stage. Actually, the strictest associations were reported in MCI participants. Longitudinal NFL level was generally increased in patients who were classified as N+ (using temporal brain atrophy as N– indicator) and in those who were only T+. Therefore, NFL might reflect a neurodegenerative process that occurred independently from Aβ pathology. Noteworthy, the NFL rate of change, rather than NFL absolute concentration, was subject to a significant increase in mutation carriers compared with non-carriers. Moreover, the NFL rate of change strongly correlated with longitudinal precuneus cortical thinning in both symptomatic and presymptomatic mutation carriers [89].

NFL as Risk/Screening Biomarker

Blood NFL levels seem to predict the progression to AD dementia in patients with subjective memory complaints [77]. An association between regional hypometabolism in the right hippocampus and higher plasma NFL levels was reported in cognitively normal participants from the ADNI database [87]. Hu and colleagues [90] explored the predictive role to develop AD of plasma NFL at the preclinical stage. Interestingly, plasma NFL concentrations were already abnormally high in cognitively normal individuals with significant Aβ-related

pathological changes. Baseline plasma NFL levels did not differ in normal elderly volunteers who remain cognitively intact during the follow-up, independently from an initial amyloid PET positivity status. Instead, a trend toward elevated plasma NFL concentration was observed in Aβ+ individuals with subjective memory complaints compared to subjects without memory complaints who were Aβ+, and plasma NFL resulted to be inversely associated with cognitive performance [91]. By contrast, other groups investigated the correlation between serum NFL levels with cerebral metabolism in MCI patients. Regional hypometabolism in bilateral parahippocampal gyri, right fusiform, and middle temporal gyri was independently predicted by plasma NFL [92].

Weston and colleagues [93] reported increased serum NFL concentrations also in symptomatic and presymptomatic familial AD (FAD) mutation carriers, showing a significant correlation with the estimated years to/from symptom onset across all mutation carriers as well as with cognitive decline and MRI atrophy. This finding suggests that increases in serum NFL precede the onset of AD symptoms. A large study in the DIAN cohort confirmed NFL as a sensitive marker of early neurodegeneration, finding significant increased serum NFL levels in AD mutation carriers (Aβ precursor protein (APP) or presenilin 1 (PSEN1) or presenilin 2 (PSEN2)) 16 years before disease onset [89]. The rate of change of serum NFL peaked in mutation carriers during the conversion phase to clinically evident cognitive impairment and reached a plateau in symptomatic carriers; absolute values of NFL showed a trend toward a slow increase over time (Table 2). Interestingly, the increase in plasma NFL concentration during the follow-up (15–30 months) in 79 elderly participants without dementia, including 15 subjects with MCI, was associated with a significant decline in both attention and global cognition and with an increase in cerebral amyloid PET uptake [32]. More recently, baseline serum NFL was shown to be a strong and independent predictor of brain volume loss and subtle cognitive changes in a longitudinal study cohort of neurologically intact individuals [79].

NFL as Predictive Biomarker

Although not yet in humans, transgenic mice models treated with a β-secretase (BACE) inhibitor showed beneficial effects on AD-relevant downstream markers, including reduced plasma NFL concentrations [30].

FTD

The term FTD indicates a heterogeneous spectrum of NDDs inexorably conveying to a dementia syndrome characterized by predominant behavioral—behavioral FTD (bvFTD) [94]—or language—primary progressive aphasia (PPA) [58]—

314 impairment. It is the third most common neurodegenerative
 315 dementia after AD and DLB and is typically diagnosed in mid-
 316 dle age [95]. bvFTD is the most prevalent phenotype (55–60%
 317 of cases) whereas PPA (40–45% of cases) can be further clas-
 318 sified as non-fluent/agrammatic variant (nfvFTD) and semantic
 319 variant (svFTD) [96]. Notably, an additional clinical PPA var-
 320 iant, named logopenic variant, can show AD pathological fea-
 321 tures in more than half of subjects [97]. Finally, a clinical over-
 322 lap between FTD and ALS is described and about 10–15% of
 323 cases with ALS report a dementia syndrome in the FTD spec-
 324 trum (ALS-FTD) [98]. The underlying pathologies in FTD,
 325 essentially abnormal accumulations of either tau or TAR
 326 DNA-binding protein 43 (TDP-43) proteins, may be recog-
 327 nized only on postmortem examination. These misfolded pro-
 328 tein aggregates lead to atrophy (structural MRI) and
 329 hypometabolism (^{18}F FDG-PET) of frontal and/or anterior tem-
 330 poral lobes depending on phenotype [41].

331 Unfortunately, with the exception of causative mutations in
 332 genetic forms (about 10% of cases: hexanucleotide repeat ex-
 333 pansion near the chromosome 9 open reading frame gene
 334 (C9orf72), progranulin (GRN), and microtubule-associated
 335 protein tau (MAPT) [99]), CSF poly(GP) detection in
 336 C9ORF72 expansion carriers, and decreased CSF/blood
 337 progranulin levels in GRN mutation carriers, specific patho-
 338 physiological biomarkers for FTD are completely lacking.
 339 However, the diagnosis of FTD remains very challenging,
 340 especially for behavioral variant as its diagnosis is mainly
 341 based on clinical assessment and because its symptoms show
 342 a significant overlap with primary psychiatric disorders [100].

343 In this context, blood NFL is a promising candidate bio-
 344 marker for FTD, especially for disease differential diagnosis,
 345 monitoring, and prognosis [101, 102]. Recent evidence
 346 proved that blood and CSF levels of NFL are tightly related
 347 and significantly higher in FTD subjects than in HC [103],
 348 without gender differences [104]. Furthermore, although
 349 NFL levels generally increase with aging, this association
 350 seems not present for FTD patients [16, 105–107]. Blood
 351 NFL levels tightly correlate with CSF values in almost all
 352 studies measuring this biomarker in both fluids, thus suggest-
 353 ing that the peripheral concentrations of NFL substantially
 354 reflect the pathophysiological modification within CNS lead-
 355 ing to NFL increase in CSF.

356 NFL as Diagnostic Biomarker

357 Serum NFL levels distinguished FTD patients from controls
 358 with good/optimal diagnostic accuracy (Table 2) [105,
 359 108–110]. Interestingly, this biomarker was higher in bvFTD
 360 individuals in comparison with psychiatric patients affected by
 361 depression, schizophrenia, and bipolar disorders [106], in
 362 which bvFTD misdiagnosis is common [100]. The diagnostic
 363 accuracy to differentiate bvFTD from psychiatric disorders was

above 80% (Table 2), independently from the specific psychi-
 atric condition (mood or psychotic disorders) [106, 107].

Only one study compared both FTD and AD subjects,
 reporting that serum NFL levels were higher in bvFTD patients
 [109], and separated the two groups with a sensitivity and spec-
 ificity of 93% and 61%, respectively (Table 2), after a prelim-
 inary exclusion of bvFTD patients with an AD biomarker pro-
 file and clinical AD subjects without a core biomarker confir-
 mation. Moreover, serum NFL concentrations seemed to be
 higher in nfvPPA and svPPA than lvPPA subjects [105],
 though with only moderate accuracy. A further study showed
 no significant differences between PPA subtypes [110].

Finally, although FTD individuals had higher serum NFL
 levels than subjects with other cognitive disorders such as AD,
 ALS patients reported even more elevated concentration
 [108]. Notably, ALS subjects present a TDP-43 pathology in
 about 95% of cases, suggesting a potential association be-
 tween increased NFL concentration and TDP-43 pathology.
 Further confirmation of this hypothesis is supported by ob-
 serving that FTD forms expected to be TDP-43 positive
 (C9ORF72 and GRN mutation carriers, or svPPA phenotype)
 reported higher concentration of this biomarker than FTD
 subtypes expected to be tau positive (MAPT mutation carriers
 and nfvPPA) [16, 99, 104].

NFL as Staging and Prognostic Biomarker

In different studies, serum NFL increases overtime in FTD
 subjects, independently from the phenotypes, with the excep-
 tion of lvPPA [105, 109]. A longitudinal Mini-Mental State
 Examination (MMSE) decline was correlated with baseline
 serum NFL levels [107]. Disease duration was not associated
 with NFL concentration although one study reported a poor
 survival in FTD subjects in the higher tertile of serum NFL
 levels (Table 2).

Additionally, peripheral blood NFL concentrations appeared
 to reflect specific regional brain atrophy related to clinical phe-
 notypes (PPAs or bvFTD). In bvFTD patients, serum NFL was
 associated with a low cognitive score and a reduction in whole-
 brain volume and was correlated with brain atrophy, including
 frontal and subcortical regions [99, 104, 109, 110].

Serum NFL was correlated with baseline cognitive impair-
 ment, cognitive decline overtime, and atrophy progression of
 the left frontal lobe and the right middle frontal gyrus in PPA
 individuals and nfvPPA/svPPA subjects, respectively [105,
 107]. On the other hand, although only in one study, serum
 NFL concentration was not related to specific hypometabolic
 regions on ^{18}F FDG-PET in PPA subjects [110].

NFL as Risk/Screening Biomarker

Noteworthy, serum NFL was higher in genetic FTD with a
 full-blown clinical picture but not in presymptomatic carriers

compared to HC, independently from the gene mutation. Moreover, it was consistently higher in converters than in non-converter carriers [104] and increased overtime in converters but not in symptomatic FTD as well as non-converters. Therefore, serum NFL could differentiate genetic FTD patients from presymptomatic carriers, with an excellent diagnostic accuracy (Table 2) [16]. By contrast, the discriminatory accuracy of the biomarker relative to presymptomatic genetic carriers and controls resulted quite poor (Table 2).

ALS

ALS is a progressive neurological disease in which upper motor neuron (UMN) and lower motor neuron (LMN) degenerate, leading to paralysis and death, typically within 3–5 years from symptom onset. To date, there is no definitive diagnostic test for ALS, and confirmation of diagnosis is based on clinical findings, electromyography results, and exclusion of mimics [52]. Despite efforts to increase the sensitivity of diagnostic criteria, often the diagnosis is made only after the onset of symptoms for both sporadic and familial ALS [111, 112]. An early diagnosis would be paramount, since it was observed that the benefit of riluzole is related to its early administration.

A large body of research exists on neurochemical ALS biomarkers [113, 114], among which phosphorylated neurofilament heavy chain (pNFH) and NFL have been postulated as the most interesting candidates [115, 116]. This is not surprising, given the axonal impairment that characterizes the disease already at the early stage, with a large release of NF in CSF [117]. Additionally, previous studies indicate cytoskeletal proteins as one of the key factors contributing to neurodegeneration in ALS [118–123]. Other evidences provide additional support that NFL aggregation is an early event in motor neuron disease [124], and that NFL is involved in the aggregation and neurotoxicity of other proteins in motor neurons [125]. At the same time, elevated NFL levels in ALS may be explained by the higher content of axonal proteins in motor neurons compared to other neuronal populations [126]. Nonetheless, several data highlighted that NFL is able to discriminate ALS patients from healthy and disease controls [14, 117, 127, 128], especially in cases with predominant UMN signs, and correlates with clinical disability [129], disease stage, progression, and/or prognosis [130, 131], probably reflecting the burden of motor neuron degeneration. Although CSF NFL remains the more robust fluid biomarker for ALS because of its directly reflecting alterations in the CNS, a high correlation between CSF and blood NFL concentrations has been reported [132]. Moreover, at odds with other neurodegenerative diseases such AD, NFL concentrations do not correlate with age in ALS individuals [133–135].

NFL as Diagnostic Biomarker

Mounting evidence reports significantly higher blood NFL levels in ALS patients when compared to controls (Table 2) [40, 135–138]. The diagnostic performance of serum NFL in discriminating ALS and non-neurodegenerative subjects showed excellent sensitivity and specificity (Table 2) [139, 140]. These findings led authors to propose the introduction of serum NFL measurement into clinical practice as supportive diagnostic tool. In addition, serum NFL showed significantly elevated concentration in ALS even at the onset of the first symptoms, confirming its potential role as a biomarker for early detection of symptomatic sporadic ALS. In this regard, serum NFL concentrations demonstrated optimal sensitivity and specificity also in distinguishing early symptomatic ALS from other neurologic diseases or motor neuron disease mimics, independently whether diagnosis was definite, probable, or possible, following the El Escorial criteria (Table 2) [134]. Interestingly, Gille and colleagues [135] reported an increase of serum NFL as a function of the number of regions (i.e., cranial, cervical) affected by UMN degeneration. Accordingly, in a MRI-based study, elevated CSF and serum NFL concentrations were significantly associated with lower diffusion tensor imaging (DTI) fractional anisotropy and increased radial diffusivity in the corticospinal tract of ALS patients, as well as with clinically UMN score burden [133]. On the other hand, previous studies have shown that NFL levels were not increased in Kennedy disease and spinal muscular atrophy (strictly LMN diseases) [128, 134]. As a consequence, a subclinical involvement of the UMN is likely in ALS patients with isolated LMN symptoms and elevated serum NFL concentration [117]. However, the neuroanatomical correlate of NFL increase is not yet clear since Verde and colleagues [139] showed a lack of association with DTI-MRI measurements of the integrity of cerebral white matter tracts in the brain of ALS patients. Finally, serum NFL levels were reported relatively lower in patients with primary lateral sclerosis (PLS) and hereditary spastic paraplegia (HSP), two UMN-isolated syndromes, compared with ALS subjects, suggesting in such patients different pathophysiological processes and rates of neurodegenerative diseases [134, 135].

NFL as Staging and Prognostic Biomarker

Several studies reported that blood NFL levels correlate with disease severity parameters, such as the decline in the ALS Functional Rating Scale-Revised (ALSFRS-R) score and the ALS Milano-Torino Staging (MITOS) system score [135, 137, 140, 141].

Furthermore, serum NFL levels at recruitment or at the time of diagnosis predicted survival independently from other clinical variables and were negatively associated with disease duration (Table 2) [136, 138, 142]. Thouvenot and colleagues

[140] evaluated the largest series ever of serum samples taken from ALS patients, finding that NFL concentration was the most important parameter related to ALS survival in multivariate models (Table 2). Likewise, serum NFL concentrations in the middle and high tertile were associated with an increased HR compared with those of patients in the lowest tertile (Table 2) [135]. Interestingly, unlike pNFH, NFL levels seem to change minimally throughout the course of the disease, maintaining distinct temporal profiles from controls, and a steady trajectory [136].

However, not all studies confirmed blood NFL as a robust prognostic biomarker in ALS patients, even if all proved lower NFL concentration in slow disease progressors [141]. Notably, the ALSFRS-R and the ALS MITOS system better correlated with CSF than serum at the baseline [137]. No significant correlation has been found between blood NFL levels and cognitive dysfunction in ALS [135].

NFL as Risk/Screening Biomarker

In contrast with AD, CSF and blood NFL levels are reported normal in presymptomatic ALS mutation carriers (C9orf72, SOD1, FUS/TLS, or TARDBP), but they increase suddenly with symptom onset in symptomatic mutation carriers as demonstrated by Weydt and colleagues [143]. Furthermore, using the parental age of disease onset as a proxy for assumed age of clinical onset, any trend toward an increase of NFL concentration was observed in asymptomatic mutation carriers. Despite recent longitudinal data on a large cohort of presymptomatic, SOD1 mutation carriers provided evidence that an increase in CSF and blood NFL levels occurs at least 1 year before of any clinical manifestations of the disease [144].

NFL as Predictive Biomarker

It would be interesting to determine whether riluzole reduces blood NFL levels over time given its neuroprotective effects and, although minimally, its capacity to slow disease progression. Currently, no studies investigated blood NFL as an indicator of treatment response in ALS, and no difference in blood NFL levels between patients treated and not treated with riluzole has been reported so far [136, 139]. On the other hand, recent studies on spinal muscular atrophy (SMA), a group of severe autosomal recessively inherited neurodegenerative disorders characterized by degeneration of the spinal alpha motor neurons, have highlighted an emerging role of NFL in tracking disease progression and response to treatment. Of note, recent data provided evidence that CSF NFL levels normalize and correlate with motor improvement in children with SMA treated with nusinersen, with a greatest benefit found in children who received treatment earliest during the course of disease [145]. Nusinersen, an antisense oligonucleotide delivered intrathecally by a spinal tap, is the first drug clinically

approved for the treatment of all SMA types, with a rather dramatic impact on phenotype [146]. The levels of two additional biomarkers of neurodegeneration (CSF tau and glial fibrillary acidic protein (GFAP), an intermediate filament present in astrocytes) decreased together with CSF NFL after nusinersen administration, indicating that the neuronal and astroglia damage can be restored by nusinersen treatment [145]. Moreover, the decrease of NFL concentration was much larger than that of tau and GFAP, suggesting NFL as an early treatment response biomarker in SMA patients, helpful to select those patients will benefit to continue such an invasive treatment. Further studies with a long follow-up are needed, but these preliminary results in SMA indicated NFL as a promising marker for upcoming disease-modifying therapies in diseases beside SMA. Conversely, it is worth mentioning that the diagnostic and monitoring value of NFL in CSF and blood has not been confirmed in adolescent and adult SMA-type (SMA types 2 and 3) patients treated with nusinersen [134, 147]. It was hypothesized that NFL release is lower in late-onset SMA than in the infantile-onset subtype. Actually, the first phenotype is characterized by a long-lasting and chronic disease course while the foster by an acute and highly aggressive onset. Additionally, subjects with infantile-onset SMA report a significantly better response to nusinersen therapy when compared to individuals with adult-onset one. In this regard, the finding of normal blood levels of NFL in SMA could be used in a diagnostic panel of biochemical markers to help differentiate patients presenting with motor neuron deficits, separating SMA from ALS. Indeed, a substantial proportion of patients with SMA initially receive a diagnosis of ALS [148].

Degenerative Parkinsonisms

PD is the most common degenerative parkinsonism, with evidence of progressive loss of dopaminergic neurons in the pars compacta of the substantia nigra. Diagnostic criteria have been recently revised to improve diagnostic accuracy imaging biomarkers as supportive features [61]. However, early diagnosis and progression prediction remain challenging for physicians. Of note, the differential diagnosis between PD and AP can be difficult, mainly at the early clinical stage. Similarly, evolution of diagnostic criteria for AP improved accuracy, but misdiagnosis rates are still high [149–152]. The APs that most commonly mimic PD are progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), whereas among APs, the lowest diagnostic accuracy regards the corticobasal degeneration (CBD).

Currently, biochemical biomarkers for PD and AP are an unmet need, but many CSF/serum molecules are under evaluation. CSF NFL concentration overlaps in patients with PD, PD with dementia (PDD), and DLB and are comparable with

those in HC [31]. In contrast, it has been demonstrated that CSF NFL levels are markedly increased in AP patients. Accordingly, it might discriminate between PD and AP with a high degree of diagnostic accuracy [17, 18, 153, 154]. This is in line with the remarkable axonal degeneration of large myelinated axons occurring in AP as well as with the rapid neuronal loss in such conditions [155]. Furthermore, CSF NFL concentration correlates with measures of disease severity and other clinical variables, demonstrating its capability to reflect neurodegenerative mechanisms. However, to overcome the well-known limits related to CSF examination, blood-derived NFL would be a more favorable biomarker. In this regard, the strong correlation between blood and CSF NFL levels in parkinsonian syndromes holds potential for an application in clinical practice [156].

PD

NFL as Diagnostic Biomarker

Similar to CSF results, NFL concentration in serum/plasma is considered useful for a differential diagnosis between PD and AP [157]. This has been tested for the first time in three independent prospective cohorts of PD, PSP, MSA, and CBD patients, compared with HC. Blood NFL levels in AP were significantly elevated compared with those in PD, showing a diagnostic accuracy ranging from good (in the early cohort with disease duration < 3 years) to excellent (in the Lund cohort) (Table 2) [156]. Conversely, blood NFL levels were not able to accurately separate PD from HC. A subsequent study in subjects with an uncertain diagnosis at the time of inclusion confirmed similar results (Table 2) [158]. Nevertheless, recent studies support the promise of plasma NFL as a diagnostic biomarker also in PD, demonstrating relatively higher NFL levels in cases vs controls [159] and a good diagnostic accuracy in differentiating PD patients from HC (Table 2) [160]. Moreover, higher serum NFL levels were found even at early stages of the disease and in participants at risk of disease progression (prodromal PD and symptomatic and asymptomatic mutation carriers of known PD genetic mutations), indicating the presence of active disease and potential for conversion to either PD or parkinsonian syndromes [161].

NFL as Staging and Prognostic Biomarker

Heterogeneous results regarding possible correlations between blood NFL and PD clinical features in three independent PD cohorts have been provided in the prospective and longitudinal study of Hansson and colleagues [156]. In general, higher blood NFL levels were observed in more advanced PD and, in the Lund PD cohort, a higher blood NFL concentration was associated with disease duration and more

severe motor symptoms (measured as Hoehn and Yahr (H&Y) stage, Unified Parkinson's Disease Rating Scale (UPDRS) III motor score, Timed Up and Go Test, and Tandem Gait Test). Conversely, no clinical correlations were described in the London cohort and the early-stage disease cohort [156]. However, further studies confirmed the positive relation between plasma NFL levels and motor symptom severity (measured as H&Y stage and UPDRS part III score) and proved a significant correlation between plasma NFL concentration and cognitive dysfunction at MMSE [161, 162]. In another study, PDD patients reported higher plasma NFL level compared with PD subjects without dementia [84], supporting an association between plasma NFL and cognitive function in PD patients [84]. Furthermore, higher baseline plasma NFL concentrations in PD patients were found to be longitudinally associated with a higher risk of progression for both motor and cognitive symptoms, suggesting that serum NFL may be a biomarker of clinical progression in PD (Table 2) [160–162].

PSP

NFL as Diagnostic Biomarker

Two other studies confirmed the diagnostic value of blood NFL in PSP patients showing good capability to discriminate between PSP and HC (Table 2) [163, 164]. In contrast, blood NFL is not suitable to separate PSP from other forms of AP [156] and similar levels are reported in patients with MSA and PSP [158].

NFL as Staging and Prognostic Biomarker

Greater baseline NFL levels in serum/plasma seem to correlate with disease severity and clinical progression in PSP patients, though with conflicting results. Such heterogeneity may reflect differences in study design, since PSP patients have been evaluated as a separate group in some studies but not in others where PSP, MSA, and CBD patients have been combined as a whole group. Specifically, blood NFL levels positively correlated with motor symptom severity, evaluated as H&Y stage and with UPDRS III motor score, but not with disease duration or other clinical assessments, in the AP group (including also MSA and CBD patients) [156]. Similarly, serum NFL concentration at baseline correlated with motor performances, measured with the International Cooperative Ataxia Rating Scale score and Tandem Gait Test in another cohort of AP patients including PSP [158].

In studies focusing exclusively on PSP patients, higher serum NFL levels were related to more severe motor, functional, and cognitive disability as well as shorter survival but not with age at symptom onset or disease duration (Table 2) [163]. Notably, NFL levels in the higher tertile were

705 associated with worse survival (Table 2) [164]. Higher base-
706 line plasma NFL levels also predicted greater whole-brain
707 and superior cerebellar peduncle volume loss at 1-year fol-
708 low-up [163].

709 MSA and Degenerative Ataxias

710 NFL as Diagnostic Biomarker

711 As for PSP, studies indicate elevated blood NFL concentration
712 in MSA patients, suggesting its use in discrimination of MSA
713 from PD and HC with a good diagnostic accuracy (Table 2).
714 However, as aforementioned, NFL cannot discriminate
715 among APs [158].

716 Moreover, blood NFL was proposed to improve the differ-
717 ential diagnosis of degenerative ataxias. In a pilot study eval-
718 uating serum NFL levels in patients with a clinical diagnosis
719 of probable cerebellar-MSA (c-MSA) subtype, sporadic adult-
720 onset ataxia (SAOA), and frequent repeat-expansion
721 spinocerebellar ataxias (SCAs 1, 2, 3, and 6) and in HCs,
722 serum NFL concentration was found to be higher in SCA
723 patients and in the c-MSA group compared with controls.
724 This is probably the result of the diffuse involvement of
725 spinocerebellar and corticospinal tracts in these multisystemic
726 neurodegenerative ataxias [165]. However, the performance
727 of serum NFL differentiating c-MSA from SCAOA was only
728 moderate (Table 2), in contrast with a higher accuracy previ-
729 ously reported for CSF NFL (AUC = 0.93) [166]. NFL levels
730 were significantly lower in SCAOA and comparable with those
731 of HC. A further study investigated serum NFL concentration
732 in large cohorts of SCA-3 subjects and demonstrated higher
733 levels in both preclinical and manifest SCA-3 individuals
734 compared with HC [167]. Serum NFL levels discriminated
735 manifest SCA-3 from HC with excellent accuracy, and the
736 diagnostic performance remained good in distinguishing pre-
737 clinical SCA-3 subjects from HC (Table 2) [167]. Recently,
738 plasma NFL concentrations resulted higher also in patients
739 affected by Friedreich's ataxia (FA), which is the most com-
740 mon autosomal recessive ataxia caused by CAG repeat expan-
741 sion in the ATXN3/MJD1 gene, compared with aged-
742 matched controls [168].

743 NFL as Staging and Prognostic Biomarker

744 Serum NFL in c-MSA patients does not seem to correlate with
745 clinical disease severity (as assessed by the Scale for the
746 Assessment and Rating of Ataxia (SARA)) or disease progres-
747 sion [165]. Similarly, a recent study in 99 patients with genet-
748 ically confirmed FA did not find a correlation with disease
749 severity (as defined by SARA score), age at onset, or disease
750 duration [169]. Moreover, serum NFL concentration remains

stable in a subgroup of 14 FA patients who received a 2-year
follow-up evaluation [169].

Conversely, serum NFL concentration increased with dis-
ease severity in a large cohort of SCA-3 patients, including
manifest and preclinical individuals, and correlated with both
clinical scales (according to SARA and International
Cooperative Ataxia Rating Scale (ICARS) scores) and reduc-
tion of cerebellar and brainstem volume [167]. Preclinical
SCA-3 group was divided in early and late preclinical sub-
groups using the median predicted number of years to onset of
manifest disease. Serum NFL concentrations resulted higher
in manifest than preclinical SCA-3 subjects and in late pre-
clinical SCA-3 subjects compared with early preclinical SCA-
3 individuals. However, no differences were observed be-
tween early preclinical subjects and HC [167]. Despite CAG
repeat count is a well-known prognostic factor for SCA-3 and
FA, a correlation between serum NFL and CAG repeat lengths
has been inconsistently reported [168, 169].

NFL as Risk/Screening Biomarker

In their study on 133 SCA-3 patients, Li and colleagues [167]
demonstrated higher serum NFL concentrations in 26 preclin-
ical ATXN3 mutation carriers (patients with SARA score < 3)
compared with controls. Moreover, a correlation between mo-
tor symptoms, neuroimaging markers, and serum NFL was
found in all ATXN3 mutation carriers, suggesting that NFL
may serve to track neurodegeneration and disease progression
already in pre and prodromal SCA-3 phases.

751 HD

752 Among the most common neurodegenerative diseases, HD is
753 unique, since the major part ($\approx 99\%$) of individuals presenting
754 a HD phenotype have a mutation in the same gene [170].
755 Indeed, HD is an autosomal dominant inherited neurodegen-
756 erative disease with the typical manifestations of involuntary
757 movements, psychiatric symptoms, and cognitive decline.
758 The etiological basis is the deleterious expansion of
759 polyglutamine encoding CAG repeats in the huntingtin
760 (HTT) gene, leading to the expression of neurotoxic mutant
761 huntingtin (mHTT) and extensive degeneration of neurons
762 primarily occurring in the striatum and cortex [171]. The dis-
763 ease usually starts in midlife, with age of onset inversely cor-
764 relating to CAG repeat number [171]. Although the cause is
765 known, disease-modifying treatments are not yet available. In
766 HD, a reliable genetic test confirms a clinical diagnosis in
767 symptomatic people or predicts disease onset in asymptomatic
768 mutation carriers [172]. As a consequence, a novel biomarker
769 should be directed to track disease progression and predict a
770 treatment response to targeted therapies. Although not conclu-
771 sive, the results of the available studies display that blood NFL

799 could have a role in this context. Previous reports on CSF
800 NFL indicate elevated concentrations in HD subjects [19,
801 173, 174]. This is not surprising because mtHTT interacts with
802 other proteins altering their function and finally leading to
803 abnormal protein aggregation and impaired axonal transport
804 [175]. Furthermore, the level of misfolded mtHTT protein
805 correlates with NFL concentration in CSF, thus suggesting a
806 contemporary releasing of both proteins from damaged neu-
807 rons [176].

808 **NFL as Staging and Prognostic Biomarker**

809 In the first retrospective study investigating NFL concentra-
810 tions in the blood of premanifest HD (preHD) and early-stage
811 HD patients enrolled in the TRACK-HD cohort, Byrne and
812 colleagues [177] showed higher baseline NFL levels in 201
813 HTT mutation carriers, including 58 with early premanifest
814 and 46 subjects with late premanifest disease, than in controls.
815 Moreover, NFL concentration reflected baseline motor and
816 cognitive deficits in HD patients and differed significantly
817 with increasing disease stage. Positive associations were
818 found between plasma NFL concentration, age, and CAG
819 triplet repeat counts, with higher CAG lengths being associat-
820 ed with earlier and steeper increases in plasma NFL [177].
821 Therefore, NFL is the first biofluid marker showing a direct
822 relationship with a causative gene expansion [178].

823 Of note, baseline plasma NFL predicted rates of brain at-
824 rophy, cognitive decline, and worsening of functional ability
825 and motor performance in mtHTT carriers [177].
826 Interestingly, it was closely associated with the rate of
827 whole-brain atrophy than with the rate of striatal one, suggest-
828 ing that plasma NFL reflects more the rate of global neuronal
829 degeneration than that of a specific brain area [177].
830 Additionally, in the same TRACK-HD cohort, Johnson and
831 colleagues [179] showed voxel-wise region-specific associa-
832 tions between plasma NFL levels and both cross-sectional and
833 longitudinal MRI cortical thinning and white matter volume
834 reduction, highlighting the value of NFL as a dynamic and
835 robust marker of brain atrophy. Notably, higher concentra-
836 tions of NFL in plasma were associated with lower volume
837 in regions known to be affected in HD and predicted subse-
838 quent occipital gray matter atrophy and widespread white mat-
839 ter reduction over the 3-year follow-up, independently of age
840 and CAG length repeats [179]. NFL increased significantly
841 from baseline both in individuals with premanifest HD and
842 in those with manifest HD [179]. Remarkably, in a subsequent
843 study, Byrne and colleagues [180], combining CSF/plasma
844 NFL and CSF mutant huntingtin protein (mHTTp) as biofluid
845 biomarkers, demonstrated that NFL levels were more accurate
846 than mHTTp to discriminate between premanifest and mani-
847 fest HDs and correlated with severity of symptoms better than
848 mHTTp in manifest HD.

CJD

CJD is the most common human prion disease. Approximately 850
85% of cases are sCJD, but in a minority of cases, CJD can be 851
genetically determined (gCJD) [181]. The disease is a rapidly 852
progressive and fatal neurodegenerative condition, whose differ- 853
ent phenotypes depend, at least in part, by polymorphisms on 854
the gene encoding prion protein (PrP) [182]. Diagnosis is fre- 855
quently tardive and relies on clinical World Health Organization 856
(WHO) criteria supported by detection of the 14-3-3 protein 857
and, more recently, t-tau in the CSF [66, 183, 184]. Also, CSF 858
NFL recently demonstrated to be a reliable biomarker in the 859
CJD diagnostic workup. Although few studies explored its role 860
as a biomarker in CJD patients so far, CSF NFL levels are 861
significantly increased in CJD (including those with more slow- 862
ly progressive and atypical disease course) compared with AD, 863
FTD, other NDDs (dementia), and controls, indicating a massive 864
synaptic degeneration and neuroaxonal damage in CJD [22, 23, 865
185, 186]. Additionally, it is noteworthy that NFL concentra- 866
tions in CSF appear highly variable among different sCJD sub- 867
types, with higher NFL levels in those with more rapidly 868
progressing disease [187]. Importantly, plasma NFL correlates 869
with CSF NFL concentration and recent studies suggest that 870
blood NFL can accurately reflect the massive neurodegeneration 871
in CJD patients. 872

NFL as Diagnostic Biomarker

Diagnostic accuracy of serum NFL for discrimination be- 874
tween CJD and controls was excellent (Table 2) [185]. 875
These findings have been independently replicated in other 876
two studies. Serum NFL distinguished patients from controls 877
with 100% sensitivity and 100% specificity in 45 sCJD pa- 878
tients enrolled in the National Prion Monitoring Cohort [188]. 879
Noteworthy, Kovacs and colleagues [189] reported high sen- 880
sitivity and specificity of plasma NFL concentration in dis- 881
criminating CJD subjects from non-CJD controls in a cohort 882
of 132 pathologically classified patients (sCJD, gCJD, and 883
AD cases) showing a rapidly progressive neurological picture. 884
However, in this study, the diagnostic value in the differentiat- 885
ion between prion and other disease cases resulted lower 886
than previously reported investigations (Table 2) [189]. 887
Moreover, serum NFL values have been elevated since the 888
early phases of the disease, suggesting a possible role as a 889
screening biomarker [188]. Conversely, serum NFL concen- 890
tration overlapped between ALS and CJD patients in a recent 891
prospective study, even though the size of CJD group was 892
very small [139]. 893

NFL as Staging and Prognostic Biomarker

Longitudinal changes in serum tau and NFL levels were in- 895
vestigated in the aforementioned study of Thompson and 896

colleagues [188]. However, despite a trend toward increasing concentrations of both tau and NFL over the last 12 months before death, at variance with tau, no association was found between serum NFL concentration and speed of decline on the Medical Research Council (MRC) Prion Disease Rating Scale [188]. Also, a recent study strengthens the tight association of plasma tau levels with the rate of disease progression and survival time in sCJD [190].

NFL as Risk/Screening Biomarker

gCJD forms are linked to mutations in the prion protein gene (PRNP) inherited with an autosomal dominant pattern and variable penetrance [191]. The relationship between genotype and phenotype remains a matter of debate, and index cases do not always have a family history [192]. Under this scenario, the discovery of biomarkers serving as surrogates of outcome in clinical trials may be crucial because *PRNP* mutation carriers might benefit from a presymptomatic intervention. PrP-lowering therapeutics are now in preclinical development, and to this end, CSF total PrP has demonstrated to be a strong candidate fluid biomarker showing stable low levels in an ongoing natural history study including presymptomatic mutation carriers and normal controls [193].

Conclusions

The impact of physiological variables on blood NFL concentration, such as sex and age, has not been systematically investigated across published studies. Other variables possibly affecting its modification in peripheral blood, including systemic comorbidities and concomitant drug therapies, were not taken into account. Liver and renal clearance as well as blood cell counts and plasma protein composition could affect biomarker concentrations [194]; however, these factors were not investigated. Indeed, blood NFL concentration alterations associated with renal and hepatic dysfunctions remain unknown, thus representing a potential relevant methodological bias, especially in subjects with NDDs, being generally old and frequently exhibiting vascular comorbidities. In general, blood NFL concentrations correlate with aging due to a subtle axonal degeneration and vascular changes in elderly. However, such an association was clearly absent in CJD, ALS, and AP. This suggests that the probable contribution of aging on NFL concentrations and neurodegeneration becomes trivial in highly aggressive forms of NDDs [195].

Blood NFL concentrations are reported to be massively elevated in ALS patients, even in early disease stages, indicating its value as an efficacious, yet unspecific, biomarker in the differential diagnosis of ALS from ALS mimics. Moreover, blood NFL concentrations can reflect disease severity and/or progression in ALS, suggesting that peripheral NFL could

contribute to support ALS prognosis. Other confounding variables, such as the discordant disease progression in the different clinical subtypes of ALS, should be elucidated in further studies. Actually, blood NFL could help better stratify the multifaceted clinical presentation of ALS phenotypes. However, further studies are needed to confirm its prognostic value. In contrast with genetic forms of AD, blood NFL concentrations are not increased in presymptomatic ALS mutation carriers appearing to tightly link to the symptomatic phase of the disease.

Another NDD where blood NFL increases result impressively is CJD. Because of early diagnosis remains challenging, NFL might be a reliable screening blood-based biomarker with a potentially high negative predictive value for CJD subjects, ruling out more common and less aggressive neurodegenerative dementia, such as AD. Definitely, blood NFL could be of usefulness as a first-step examination to promptly detect CJD during its prodromal phase and to start future disease-modifying treatments. On the other hand, preliminary findings do not support a potential use of NFL as a predictor of longitudinal disease progression in CJD, and its specificity should be further substantiated in comparison with other highly aggressive forms of NDD.

All reported studies showed a good or even excellent diagnostic performance of blood NFL in distinguishing patients with neurodegenerative disorders from HC. The potential contribution of this biomarker candidate to discriminate between different dementia disorders remains ambiguous given the lack of pathognomonic specificity. However, mounting data suggest that blood NFL could be a useful diagnostic tool in the diagnostic workup of FTD, to distinguish FTD (especially FTD with a TDP-43 pathology) from AD patients and to identify PPA with a likely underlying AD pathology, including lvPPA. Moreover, it can represent a biomarker tracking the disease progression and potentially identifying the transition phase from the presymptomatic to the symptomatic stage of the genetic forms of the disease. Most importantly, serum NFL is assumed to be a promising screening tool to rule out an underlying neurodegenerative disease in individuals with psychiatric disorders.

In AD, blood NFL may predict progression to dementia in individuals with MCI at high risk and identify preclinical AD before the conversion phase. Moreover, NFL captures early neurodegenerative changes in presymptomatic familiar AD mutation carriers in which blood NFL concentrations correlate with the predicted time to symptom onset. Further studies are crucial to calculate the negative predictive value of blood NFL as a screening tool in large and selected cohorts of individuals at risk of neurodegeneration and AD, such as individuals with subjective memory complaints and/or decline, late-onset psychiatric disorders, cerebrovascular disease, and diabetes, as well as in aging and elderly individuals in general.

Because of the high negative predictive value of elevated blood NFL concentrations in excluding PD, this candidate biomarker can represent a valid screening tool for clinicians in the early differential diagnosis between PD and AP in cases with confounding clinical presentations. In contrast, blood NFL measurements do not suffice to differentiate PD patients from controls and cannot be used to separate PSP, MSA, and CBD from each other. Nevertheless, blood NFL may be a prognostic tool in clinical practice in both PD and AP patients. Currently, to the best of our knowledge, there are no studies investigating blood NFL in patients with DLB, and few studies are available for PDD patients.

Regarding other relevant clinical neurological presentations, blood NFL may support the classification of sporadic late-onset ataxias, notably helping in differentiating c-MSA-C from SAOA. In choreic patients, blood NFL appears to be a robust prognostic biomarker of HD disease onset and progression and holds potential as a predictive biomarker of response to disease-modifying agents in clinical trials.

Finally, blood NFL seems to be a promising candidate predictor of the timing of clinical phenoconversion in pre-symptomatic mutation carriers with AD, HD, and SCA-3. Conversely, blood NFL concentrations are mostly normal in premanifest ALS and FTD mutation carriers but promptly increase with the onset of clinical symptoms.

In general, given the rapid advances in elucidating the pathophysiological mechanisms of diseases, at the molecular diagnostic level, biomarkers are excellent flexible tools to improve and inform all phases of drug discovery and development by enabling validation of mechanisms of actions [196, 197]. For this reason, NFL is assumed to act as an innovative molecular mechanistic biomarker supporting in vivo detection and the measurement of definite pathophysiological mechanisms across the spectrum of different NDDs. Together with other innovative molecular indicators, NFL will help establish panels of biomarkers—i.e., molecular signatures—encompassing the entire spectrum of molecular events of the NDD spectrum disorders. Applying these molecular signatures in longitudinal investigations will be critical to provide information to depict the pathophysiological processes characterizing different NDDs [198]. These innovative biomarkers will enable the selection of the most appropriate therapies for individual patients by defining which molecular pathophysiological events account for the patient’s clinical symptoms at different stages of the disease [199, 200]. This will establish the grounds to develop effective targeted treatment strategies—i.e., “molecularly” targeted therapies—for the accurate treatment of specific molecular pathophysiological pathways. Future developments in investigating NDD heterogeneity will allow clinicians to deliver targeted interventions that are “customized,” i.e., tailored, to the definite profiles of the individual NDD patient, according to the precision medicine paradigm. Such a precision medicine-based strategy is now increasingly

facing the clinical and biological/genetic complexity and heterogeneity of the various forms of NDD [198]. Precision medicine emphasizes the need of clinical medicine to focus on the pathophysiology of the individual patient, with his/her own distinctive, diverse, and complex matrix of multisystem features [200]. Concerted global efforts will pave the way for a future of neurology, in which drugs will timely and effectively support the prevention and treatment of diseases with very precise biomarker-guided targeted approaches for the right patient at the right time [201].

Acknowledgments H.H. is an employee of Eisai Inc. This work has been performed during his previous position at Sorbonne University, Paris, France. At Sorbonne University, he was supported by the AXA Research Fund, the “Fondation partenariale Sorbonne Université,” and the “Fondation pour la Recherche sur Alzheimer,” Paris, France.

Compliance with Ethical Standards

Competing Interests S.L. received lecture honoraria from Roche and Servier.

H.H. is an employee of Eisai Inc. and serves as Senior Associate Editor for the Journal Alzheimer’s & Dementia and does not receive any fees or honoraria since May 2019; before May 2019, he had received lecture fees from Servier, Biogen, and Roche; research grants from Pfizer, Avid, and MSD Avenir (paid to the institution); travel funding from Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics; and consultancy fees from Qynapse, Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare, Oryzon Genomics, and Functional Neuromodulation, and he also participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eisai, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics, and Roche Diagnostics.

He is co-inventor in the following patents as a scientific expert and has received no royalties:

- In Vitro Multiparameter Determination Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number: 8916388
- In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number: 8298784
- Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20120196300
- In Vitro Multiparameter Determination Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100062463
- In Vitro Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100035286
- In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number: 20090263822
- In Vitro Method for the Diagnosis of Neurodegenerative Diseases Patent Number: 7547553
- CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number: 20080206797
- In Vitro Method for the Diagnosis of Neurodegenerative Diseases Publication Number: 20080199966
- Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20080131921

1107 G.P., S.M., A.D.V., G.S., U.B., C.A., R.C., and F.B. declare that they
1108 have no conflicts of interest relevant to this work.

References

- 1110 1. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010)
1111 Mechanisms underlying inflammation in neurodegeneration. *Cell*
1112 140(6):918–934
- 1113 2. Heemels MT (2016) Neurodegenerative diseases. *Nature*
1114 539(7628):179
- 1115 3. Chi H, Chang HY, Sang TK (2018) Neuronal cell death mecha-
1116 nisms in major neurodegenerative diseases. *Int J Mol Sci* 19(10):
1117 3082
- 1118 4. Hampel H, Toschi N, Baldacci F et al (2018) Alzheimer's disease
1119 biomarker-guided diagnostic workflow using the added value of
1120 six combined cerebrospinal fluid candidates: A β_{1-42} , total-tau,
1121 phosphorylated-tau, NFL, neurogranin, and YKL-40. *Alzheimers Dement* 14(4):492–501
- 1122 5. Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as
1123 biomarkers in neurological disorders. *Nat Rev Neurol* 14(10):
1124 577–589
- 1125 6. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L,
1126 Zetterberg H (2019) Neurofilament light chain as a biomarker in
1127 neurological disorders. *J Neurol Neurosurg Psychiatry* 90(8):870–
1128 881
- 1129 7. Zhao Y, Xin Y, Meng S, He Z, Hu W (2019) Neurofilament light
1130 chain protein in neurodegenerative dementia: a systematic review
1131 and network meta-analysis. *Neurosci Biobehav Rev* 102:123–138
- 1132 8. Kanaan NM, Pigino GF, Brady ST, Lazarov O, Binder LI, Morfini
1133 GA (2013) Axonal degeneration in Alzheimer's disease: when
1134 signaling abnormalities meet the axonal transport system. *Exp*
1135 *Neurol* 246:44–53
- 1136 9. Yuan A, Rao MV, Veeranna NRA (2012) Neurofilaments at a
1137 glance. *J Cell Sci* 125:3257–3263
- 1138 10. Zetterberg H (2016) Neurofilament light: a dynamic cross-disease
1139 fluid biomarker for neurodegeneration. *Neuron* 91(1):1–3
- 1140 11. Liu Q, Xie F, Siedlak SL et al (2004) Neurofilament proteins in
1141 neurodegenerative diseases. *Cell Mol Life Sci* 61(24):3057–3075
- 1142 12. Yuan A, Rao MV, Veeranna NRA (2017) Neurofilaments and
1143 neurofilament proteins in health and disease. *Cold Spring Harb*
1144 *Perspect Biol* 9(4):a018309
- 1145 13. Petzold A, Keir G, Warren J, Fox N, Rossor MN (2007) A sys-
1146 tematic review and meta-analysis of CSF neurofilament protein
1147 levels as biomarkers in dementia. *Neurodegener Dis* 4(2–3):
1148 185–194
- 1149 14. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C
1150 (1996) Patients with amyotrophic lateral sclerosis and other neu-
1151 rodegenerative diseases have increased levels of neurofilament
1152 protein in CSF. *J Neurochem* 67(5):2013–2018
- 1153 15. Landqvist Waldo M, Frizell Santillo A et al (2013) Cerebrospinal
1154 fluid neurofilament light chain protein levels in subtypes of
1155 frontotemporal dementia. *BMC Neurol* 13:54
- 1156 16. Meeter LH, Dopper EG, Jiskoot LC et al (2016) Neurofilament
1157 light chain: a biomarker for genetic frontotemporal dementia. *Ann*
1158 *Clin Transl Neurol* 3(8):623–636
- 1159 17. Hall S, Öhrfelt A, Constantinescu R et al (2012) Accuracy of a
1160 panel of 5 cerebrospinal fluid biomarkers in the differential diag-
1161 nosis of patients with dementia and/or parkinsonian disorders.
1162 *Arch Neurol* 69(11):1445–1452
- 1163 18. Magdalinou NK, Paterson RW, Schott JM et al (2015) A panel of
1164 nine cerebrospinal fluid biomarkers may identify patients with
1165 atypical parkinsonian syndromes. *J Neurol Neurosurg Psychiatry*
1166 86(11):1240–1247
- 1167 19. Vinther-Jensen T, Börnsen L, Budtz-Jørgensen E et al (2016)
1168 Selected CSF biomarkers indicate no evidence of early neuroin-
1169 flammation in Huntington disease. *Neurol Neuroimmunol*
1170 *Neuroinflamm* 3(6):e287
- 1171 20. Lista S, Toschi N, Baldacci F et al (2017) Diagnostic accuracy of
1172 CSF neurofilament light chain protein in the biomarker-guided
1173 classification system for Alzheimer's disease. *Neurochem Int*
1174 108:355–360
- 1175 21. Zetterberg H, Skillbäck T, Mattsson N et al (2016) Association of
1176 cerebrospinal fluid neurofilament light concentration with
1177 Alzheimer disease progression. *Jama Neurol* 73(1):60–67
- 1178 22. van Eijk JJ, van Everbroeck B, Abdo WF, Kremer BP, Verbeek
1179 MM (2010) CSF neurofilament proteins levels are elevated in
1180 sporadic Creutzfeldt-Jakob disease. *J Alzheimers Dis* 21(2):569–
1181 576
- 1182 23. Kanata E, Golanska E, Villar-Piqué A et al (2019) Cerebrospinal
1183 fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob
1184 disease. *J Clin Neurosci* 60:124–127
- 1185 24. Lycke JN, Karlsson JE, Andersen O, Rosengren LE (1998)
1186 Neurofilament protein in cerebrospinal fluid: a potential marker
1187 of activity in multiple sclerosis. *J Neurol Neurosurg Psychiatry*
1188 64:402–404
- 1189 25. Yilmaz A, Blennow K, Hagberg L et al (2017) Neurofilament
1190 light chain protein as a marker of neuronal injury: review of its
1191 use in HIV-1 infection and reference values for HIV-negative
1192 controls. *Expert Rev Mol Diagn* 17(8):761–770
- 1193 26. Shahim P, Tegner Y, Gustafsson B et al (2016) Neurochemical
1194 aftermath of repetitive mild traumatic brain injury. *JAMA Neurol*
1195 73(11):1308–1315
- 1196 27. Pujol-Calderón F, Portelius E, Zetterberg H, Blennow K,
1197 Rosengren LE, Höglund K (2019) Neurofilament changes in se-
1198 rum and cerebrospinal fluid after acute ischemic stroke. *Neurosci*
1199 *Lett* 698:58–63
- 1200 28. Pawlitzki M, Butryn M, Kirchner F et al (2019) CSF
1201 Neurofilament light chain level predicts axonal damage in cere-
1202 bral vasculitis. *Ann Clin Transl Neurol* 6(6):1134–1137
- 1203 29. Skillbäck T, Farahmand B, Bartlett JW et al (2014) CSF neurofil-
1204 ament light differs in neurodegenerative diseases and predicts se-
1205 verity and survival. *Neurology* 83(21):1945–1953
- 1206 30. Bacioglu M, Maia LF, Preische O et al (2016) Neurofilament light
1207 chain in blood and CSF as marker of disease progression in mouse
1208 models and in neurodegenerative diseases. *Neuron* 91:56–66
- 1209 31. Bridel C, van Wieringen WN, Zetterberg H et al (2019)
1210 Diagnostic value of cerebrospinal fluid neurofilament light pro-
1211 tein in neurology: a systematic review and meta-analysis. *Jama*
1212 *Neurol* 76(9):1035–1048
- 1213 32. Mielke MM, Syrjanen JA, Blennow K et al (2019) Plasma and
1214 CSF neurofilament light: relation to longitudinal neuroimaging
1215 and cognitive measures. *Neurology* 93(3):e252–e260
- 1216 33. Molinuevo JL, Ayton S, Batrla R et al (2018) Current state of
1217 Alzheimer's fluid biomarkers. *Acta Neuropathol* 136(6):821–853
- 1218 34. Hampel H, Lista S, Khachaturian ZS (2012) Development of bio-
1219 markers to chart all Alzheimer's disease stages: the royal road to
1220 cutting the therapeutic Gordian Knot. *Alzheimers Dement* 8(4):
1221 312–336
- 1222 35. Baldacci F, Lista S, Garaci F, Bonuccelli U, Toschi N, Hampel H
1223 (2016) Biomarker-guided classification scheme of neurodegener-
1224 ative diseases. *J Sport Health Sci* 5(4):383–387
- 1225 36. Hampel H, Frank R, Broich K et al (2010) Biomarkers for
1226 Alzheimer's disease: academic, industry and regulatory perspec-
1227 tives. *Nat Rev Drug Discov* 9(7):560–574
- 1228 37. Blennow K, Hampel H, Weiner M, Zetterberg H (2010)
1229 Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.
1230 *Nat Rev Neurol* 6(3):131–144
- 1231

- 1232 38. Zetterberg H, Blennow K (2018) From cerebrospinal fluid to
1233 blood: the third wave of fluid biomarkers for Alzheimer's disease.
1234 *J Alzheimers Dis* 64(s1):S271–S279
- 1235 39. Kuhle J, Barro C, Andreasson U et al (2016) Comparison of three
1236 analytical platforms for quantification of the neurofilament light
1237 chain in blood samples: ELISA, electrochemiluminescence immu-
1238 noassay and Simoa. *Clin Chem Lab Med* 54(10):1655–1661
- 1239 40. Gaiottino J, Norgren N, Dobson R et al (2013) Increased neuro-
1240 filament light chain blood levels in neurodegenerative neurologi-
1241 cal diseases. *PLoS One* 8(9):e75091
- 1242 41. Baldacci F, Mazzucchi S, Della Vecchia A et al (2020) The path to
1243 biomarker-based diagnostic criteria for the spectrum of neurode-
1244 generative diseases. *Expert Rev Mol Diagn* 20(4):421–441
- 1245 42. Califf RM (2018) Biomarker definitions and their applications.
1246 *Exp Biol Med (Maywood)* 243(3):213–221
- 1247 43. Biomarkers Definitions Working Group (2001) Biomarkers and
1248 surrogate endpoints: preferred definitions and conceptual frame-
1249 work. *Clin Pharmacol Ther* 69(3):89–95
- 1250 44. Chen XH, Huang S, Kerr D (2011) Biomarkers in clinical medi-
1251 cine. *IARC Sci Publ* 163:303–322
- 1252 45. McKhann G, Drachman D, Folstein M, Katzman R, Price D,
1253 Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease:
1254 report of the NINCDS-ADRDA Work Group under the auspices
1255 of Department of Health and Human Services Task Force on
1256 Alzheimer's Disease. *Neurology* 34:939–944
- 1257 46. McKhann GM, Knopman DS, Chertkow H et al (2011) The diag-
1258 nosis of dementia due to Alzheimer's disease: recommendations
1259 from the National Institute on Aging-Alzheimer's Association
1260 workgroups on diagnostic guidelines for Alzheimer's disease.
1261 *Alzheimers Dement* 7:263–269
- 1262 47. Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining
1263 the preclinical stages of Alzheimer's disease: recommendations
1264 from the National Institute on Aging-Alzheimer's Association
1265 workgroups on diagnostic guidelines for Alzheimer's disease.
1266 *Alzheimers Dement* 7:280–292
- 1267 48. Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of
1268 mild cognitive impairment due to Alzheimer's disease: recom-
1269 mendations from the National Institute on Aging-Alzheimer's
1270 Association workgroups on diagnostic guidelines for
1271 Alzheimer's disease. *Alzheimers Dement* 7:270–279
- 1272 49. Dubois B, Feldman HH, Jacova C et al (2014) Advancing research
1273 diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
1274 *Lancet Neurol* 13:614–629
- 1275 50. Brooks BR (1994) El Escorial World Federation of Neurology
1276 criteria for the diagnosis of amyotrophic lateral sclerosis.
1277 Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral
1278 Sclerosis of the World Federation of Neurology Research Group
1279 on Neuromuscular Diseases and the El Escorial "Clinical limits of
1280 amyotrophic lateral sclerosis" workshop contributors. *J Neurol Sci*
1281 124(Suppl):96–107
- 1282 51. Costa J, Swash M, de Carvalho M (2012) Awaji criteria for the
1283 diagnosis of amyotrophic lateral sclerosis: a systematic review.
1284 *Arch Neurol* 69:1410–1416
- 1285 52. Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B,
1286 van den Berg LH (2016) Amyotrophic lateral sclerosis: moving
1287 towards a new classification system. *Lancet Neurol* 15(11):1182–
1288 1194
- 1289 53. McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guide-
1290 lines for the clinical and pathologic diagnosis of dementia with
1291 Lewy bodies (DLB): report of the consortium on DLB internation-
1292 al workshop. *Neurology* 47(5):1113–1124
- 1293 54. McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and
1294 management of dementia with Lewy bodies: third report of the
1295 DLB Consortium. *Neurology* 65(12):1863–1872
- 1296 55. McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and
1297 management of dementia with Lewy bodies: fourth consensus
1298 report of the DLB Consortium. *Neurology* 89(1):88–100
- 1299 56. Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal
1300 lobar degeneration: a consensus on clinical diagnostic criteria.
1301 *Neurology* 51:1546–1554
- 1302 57. Piguet O, Hornberger M, Mioshi E, Hodges JR (2011)
1303 Behavioural-variant frontotemporal dementia: diagnosis, clinical
1304 staging, and management. *Lancet Neurol* 10:162–172
- 1305 58. Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011)
1306 Classification of primary progressive aphasia and its variants.
1307 *Neurology* 76:1006–1014
- 1308 59. Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the
1309 pathogenesis of idiopathic Parkinson's disease. *J Neurol*
1310 *Neurosurg Psychiatry* 51:745–752
- 1311 60. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for
1312 Parkinson disease. *Arch Neurol* 56(1):33–39
- 1313 61. Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnos-
1314 tic criteria for Parkinson's disease: MDS-PD clinical diagnostic
1315 criteria. *Mov Disord* 30(12):1591–1601
- 1316 62. Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for
1317 the diagnosis of progressive supranuclear palsy (Steele-
1318 Richardson-Olszewski syndrome): report of the NINDS-SPSP in-
1319 ternational workshop. *Neurology* 47:1–9
- 1320 63. Gilman S, Wenning GK, Low PA et al (2008) Second consensus
1321 statement on the diagnosis of multiple system atrophy. *Neurology*
1322 71(9):670–676
- 1323 64. Armstrong MJ, Litvan I, Lang AE et al (2013) Criteria for the
1324 diagnosis of corticobasal degeneration. *Neurology* 80(5):496–503
- 1325 65. Hoglinger GU, Respondek G, Stamelou M et al (2017) Clinical
1326 diagnosis of progressive supranuclear palsy: the movement disor-
1327 der society criteria. *Mov Disord* 32:853–864
- 1328 66. World Health Organization (2003) WHO manual for surveillance
1329 of human transmissible spongiform encephalopathies, including
1330 variant Creutzfeldt-Jakob disease <https://apps.who.int/iris/handle/10665/42656> [Accessed 30 Jan 2003]
- 1331 67. Manix M, Kalakoti P, Henry M et al (2015) Creutzfeldt-Jakob
1332 disease: updated diagnostic criteria, treatment algorithm, and the
1333 utility of brain biopsy. *Neurosurg Focus* 39:E2
- 1334 68. Xia J, Broadhurst DI, Wilson M, Wishart DS (2013) Translational
1335 biomarker discovery in clinical metabolomics: an introductory
1336 tutorial. *Metabolomics* 9(2):280–299
- 1337 69. Winblad B, Amouyel P, Andrieu S et al (2016) Defeating
1338 Alzheimer's disease and other dementias: a priority for
1339 European science and society. *Lancet Neurol* 15(5):455–532
- 1340 70. Fogel DB (2018) Factors associated with clinical trials that fail and
1341 opportunities for improving the likelihood of success: a review.
1342 *Contemp Clin Trials Commun* 11:156–164
- 1343 71. Dubois B (2018) The emergence of a new conceptual framework
1344 for Alzheimer's disease. *J Alzheimers Dis* 62(3):1059–1066
- 1345 72. Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy
1346 of the clinical diagnosis of Alzheimer disease at National Institute
1347 on Aging Alzheimer Disease Centers, 2005–2010. *J Neuropathol*
1348 *Exp Neurol* 71(4):266–273
- 1349 73. Jack CR Jr, Bennett DA, Blennow K et al (2016) A/T/N: an un-
1350 biased descriptive classification scheme for Alzheimer disease
1351 biomarkers. *Neurology* 87(5):539–547
- 1352 74. Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA re-
1353 search framework: toward a biological definition of Alzheimer's
1354 disease. *Alzheimers Dement* 14(4):535–562
- 1355 75. Hampel H, O'Bryant SE, Molinuevo JL et al (2018) Blood-based
1356 biomarkers for Alzheimer disease: mapping the road to the clinic.
1357 *Nat Rev Neurol* 14(11):639–652
- 1358 76. Ashton NJ, Leuzy A, Lim YM et al (2019) Increased plasma
1359 neurofilament light chain concentration correlates with severity
1360

- 1361 of post-mortem neurofibrillary tangle pathology and neurodegen- 1426
- 1362 eration. *Acta Neuropathol Commun* 7(1):5 1427
- 1363 77. Mattsson N, Andreasson U, Zetterberg H, Blennow K, 1428
- 1364 Alzheimer's Disease Neuroimaging Initiative (2017) 1429
- 1365 Association of plasma neurofilament light with neurodegenera- 1430
- 1366 tion in patients with Alzheimer disease. *Jama Neurol* 74(5):557– 1431
- 1367 566 1432
- 1368 78. Vågberg M, Norgren N, Dring A et al (2015) Levels and age 1433
- 1369 dependency of neurofilament light and glial fibrillary acidic pro- 1434
- 1370 tein in healthy individuals and their relation to the brain parenchy- 1435
- 1371 mal fraction. *PLoS One* 10(8):e0135886 1436
- 1372 79. Khalil M, Pirpamer L, Hofer E et al (2020) Serum neurofilament 1437
- 1373 light levels in normal aging and their association with morpholog- 1438
- 1374 ic brain changes. *Nat Commun* 11(1):812 1439
- 1375 80. Forgrave LM, Ma M, Best JR, DeMarco ML (2019) The diagnos- 1440
- 1376 tic performance of neurofilament light chain in CSF and blood for 1441
- 1377 Alzheimer's disease, frontotemporal dementia, and amyotrophic 1442
- 1378 lateral sclerosis: a systematic review and meta-analysis. 1443
- 1379 *Alzheimers Dement (Amst)* 11:730–743 1444
- 1380 81. Lewczuk P, Ermann N, Andreasson U et al (2018) Plasma neuro- 1445
- 1381 filament light as a potential biomarker of neurodegeneration in 1446
- 1382 Alzheimer's disease. *Alzheimers Res Ther* 10(1):71 1447
- 1383 82. Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K 1448
- 1384 (2019) Association between longitudinal plasma neurofilament 1449
- 1385 light and neurodegeneration in patients with Alzheimer disease. 1450
- 1386 *JAMA Neurol* 76(7):791–799 1451
- 1387 83. Pereira JB, Westman E, Hansson O, Alzheimer's Disease 1452
- 1388 Neuroimaging Initiative (2017) Association between cerebrospi- 1453
- 1389 nal fluid and plasma neurodegeneration biomarkers with brain 1454
- 1390 atrophy in Alzheimer's disease. *Neurobiol Aging* 58:14–29 1455
- 1391 84. Lin YS, Lee WJ, Wang SJ, Fuh JL (2018) Levels of plasma neu- 1456
- 1392 rofilament light chain and cognitive function in patients with 1457
- 1393 Alzheimer or Parkinson disease. *Sci Rep* 8(1):17368 1458
- 1394 85. Wang SY, Chen W, Xu W et al (2019) Neurofilament light chain 1459
- 1395 in cerebrospinal fluid and blood as a biomarker for neurodegener- 1460
- 1396 ative diseases: a systematic review and meta-analysis. *J* 1461
- 1397 *Alzheimers Dis* 72(4):1353–1361 1462
- 1398 86. Zhou W, Zhang J, Ye F et al (2017) Plasma neurofilament light 1463
- 1399 chain levels in Alzheimer's disease. *Neurosci Lett* 650:60–64 1464
- 1400 87. Benedet AL, Ashton NJ, Pascoal TA et al (2019) Plasma neuro- 1465
- 1401 filament light associates with Alzheimer's disease metabolic de- 1466
- 1402 cline in amyloid-positive individuals. *Alzheimers Dement (Amst)* 1467
- 1403 11:679–689 1468
- 1404 88. Timmers M, Tesseur I, Bogert J et al (2019) Relevance of the 1469
- 1405 interplay between amyloid and tau for cognitive impairment in 1470
- 1406 early Alzheimer's disease. *Neurobiol Aging* 79:131–141 1471
- 1407 89. Preische O, Schultz SA, Apel A et al (2019) Serum neurofilament 1472
- 1408 dynamics predicts neurodegeneration and clinical progression in 1473
- 1409 presymptomatic Alzheimer's disease. *Nat Med* 25(2):277–283 1474
- 1410 90. Hu H, Chen KL, Ou YN et al (2019) Neurofilament light chain 1475
- 1411 plasma concentration predicts neurodegeneration and clinical pro- 1476
- 1412 gression in nondemented elderly adults. *Aging (Albany NY)* 1477
- 1413 11(17):6904–6914 1478
- 1414 91. Chatterjee P, Goozee K, Sohrabi HR et al (2018) Association of 1479
- 1415 plasma neurofilament light chain with neocortical amyloid- β load 1480
- 1416 and cognitive performance in cognitively normal elderly partici- 1481
- 1417 pants. *J Alzheimers Dis* 63(2):479–487 1482
- 1418 92. Mayeli M, Mirshahvalad SM, Aghamollai V, Tafakhori A, 1483
- 1419 Abdolalizadeh A, Rahmani F (2019) Plasma neurofilament light 1484
- 1420 chain levels are associated with cortical hypometabolism in 1485
- 1421 Alzheimer disease signature regions. *J Neuropathol Exp Neurol* 1486
- Q6 1422 nlz054 1487
- 1423 93. Weston PSJ, Poole T, Ryan NS et al (2017) Serum neurofilament 1488
- 1424 light in familial Alzheimer disease: a marker of early neurodegen- 1489
- 1425 eration. *Neurology* 89(21):2167–2175 1490
94. Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of 1426
- revised diagnostic criteria for the behavioural variant of 1427
- frontotemporal dementia. *Brain* 134:2456–2477 1428
95. Erkinen MG, Kim MO, Geschwind MD (2018) Clinical neuro- 1429
- logy and epidemiology of the major neurodegenerative diseases. 1430
- Cold Spring Harb Perspect Biol* 10(4):a033118 1431
96. Bang J, Spina S, Miller BL (2015) Frontotemporal dementia. 1432
- Lancet* 386:1672–1682 1433
97. Spinelli EG, Mandelli ML, Miller ZA et al (2017) Typical and 1434
- atypical pathology in primary progressive aphasia variants. *Ann* 1435
- Neurol* 81:430–443 1436
98. Strong MJ, Abrahams S, Goldstein LH et al (2017) Amyotrophic 1437
- lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): 1438
- revised diagnostic criteria. *Amyotroph Lateral Scler Frontotemporal* 1439
- Degener* 18:153–174 1440
99. Rademakers R, Neumann M, Mackenzie IR (2012) Advances in 1441
- understanding the molecular basis of frontotemporal dementia. 1442
- Nat Rev Neurol* 8(8):423–434 1443
100. Ducharme S, Dols A, Laforce R et al (2020) Recommendations to 1444
- distinguish behavioural variant frontotemporal dementia from 1445
- psychiatric disorders. *Brain* 143(6):1632–1650 1446
101. Meeter LH, Kaat LD, Rohrer JD, van Swieten JC (2017) Imaging 1447
- and fluid biomarkers in frontotemporal dementia. *Nat Rev Neurol* 1448
- 13(7):406–419 1449
102. Zetterberg H, van Swieten JC, Boxer AL, Rohrer JD (2019) 1450
- Review: Fluid biomarkers for frontotemporal dementias. 1451
- Neuropathol Appl Neurobiol* 45(1):81–87 1452
103. Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, 1453
- Teunissen CE (2015) Discriminative and prognostic potential of 1454
- cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for 1455
- frontotemporal dementia subtypes. *Alzheimers Dement (Amst)* 1456
- 1(4):505–512 1457
104. Ende E, Meeter L, Poos J et al (2019) Serum neurofilament light 1458
- chain in genetic frontotemporal dementia: a longitudinal, 1459
- multicentre cohort study. *Lancet Neurol* 18:1103–1111 1460
105. Steinacker P, Semler E, Anderl-Straub S et al (2017) 1461
- Neurofilament as a blood marker for diagnosis and monitoring 1462
- of primary progressive aphasia. *Neurology* 88:961–969 1463
106. Al Shweiki MR, Steinacker P, Oeckl P et al (2019) Neurofilament 1464
- light chain as a blood biomarker to differentiate psychiatric disor- 1465
- ders from behavioural variant frontotemporal dementia. *J* 1466
- Psychiatr Res* 113:137–140 1467
107. Katisko K, Cajanus A, Jääskeläinen O et al (2020) Serum neuro- 1468
- filament light chain is a discriminative biomarker between 1469
- frontotemporal lobar degeneration and primary psychiatric disor- 1470
- ders. *J Neurol* 267(1):162–167 1471
108. Wilke C, Preische O, Deuschle C et al (2016) Neurofilament light 1472
- chain in FTD is elevated not only in cerebrospinal fluid, but also in 1473
- serum. *J Neurol Neurosurg Psychiatry* 87:1270–1272 1474
109. Steinacker P, Anderl-Straub S, Diehl-Schmid J et al (2018) Serum 1475
- neurofilament light chain in behavioral variant frontotemporal de- 1476
- mentia. *Neurology* 91(15):e1390–e1401 1477
110. Matias-Guiu JA, Gomez-Pinedo U, Forero L et al (2019) Plasma 1478
- neurofilament light chain in primary progressive aphasia and re- 1479
- lated disorders: clinical significance and metabolic correlates. *J* 1480
- Alzheimers Dis* 72:1–10 1481
111. Cellura E, Spataro R, Taiello AC, La Bella V (2012) Factors 1482
- affecting the diagnostic delay in amyotrophic lateral sclerosis. 1483
- Clin Neurol Neurosurg* 114(6):550–554 1484
112. Turner MR, Kiernan MC, Leigh PN, Talbot K (2009) Biomarkers 1485
- in amyotrophic lateral sclerosis. *Lancet Neurol* 8(1):94–109 1486
113. Lehnert S, Costa J, de Carvalho M et al (2014) Multicentre quality 1487
- control evaluation of different biomarker candidates for amyotro- 1488
- phic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal* 1489
- Degener* 15(5–6):344–350 1490

- 1491 114. Turner MR, Benatar M (2015) Ensuring continued progress in
1492 biomarkers for amyotrophic lateral sclerosis. *Muscle Nerve*
1493 51(1):14–18
- 1494 115. Xu Z, Henderson RD, David M, McCombe PA (2016)
1495 Neurofilaments as biomarkers for amyotrophic lateral sclerosis:
1496 a systematic review and meta-analysis. *PLoS One* 11(10):
1497 e0164625
- 1498 116. Turner MR, Gray E (2016) Are neurofilaments heading for the
1499 ALS clinic? *J Neurol Neurosurg Psychiatry* 87(1):3–4
- 1500 117. Brettschneider J, Petzold A, Süßmuth SD, Ludolph AC, Tumani
1501 H (2006) Axonal damage markers in cerebrospinal fluid are in-
1502 creased in ALS. *Neurology* 66(6):852–856
- 1503 118. Lin H, Schlaepfer WW (2006) Role of neurofilament aggregation
1504 in motor neuron disease. *Ann Neurol* 60(4):399–406
- 1505 119. Munoz DG, Greene C, Perl DP, Selkoe DJ (1988) Accumulation
1506 of phosphorylated neurofilaments in anterior horn motoneurons of
1507 amyotrophic lateral sclerosis patients. *J Neuropathol Exp Neurol*
1508 47(1):9–18
- 1509 120. Collard JF, Côté F, Julien JP (1995) Defective axonal transport in
1510 a transgenic mouse model of amyotrophic lateral sclerosis. *Nature*
1511 375(6526):61–64
- 1512 121. Lee MK, Marszalek JR, Cleveland DW (1994) A mutant neuro-
1513 filament subunit causes massive, selective motor neuron death:
1514 implications for the pathogenesis of human motor neuron disease.
1515 *Neuron* 13(4):975–988
- 1516 122. Cañete-Soler R, Silberg DG, Gershon MD, Schlaepfer WW
1517 (1999) Mutation in neurofilament transgene implicates RNA pro-
1518 cessing in the pathogenesis of neurodegenerative disease. *J*
1519 *Neurosci* 19(4):1273–1283
- 1520 123. Nie Z, Wu J, Zhai J et al (2002) Untranslated element in neurofil-
1521 ament mRNA has neuropathic effect on motor neurons of trans-
1522 genic mice. *J Neurosci* 22(17):7662–7670
- 1523 124. Zhai J, Lin H, Julien JP, Schlaepfer WW (2007) Disruption of
1524 neurofilament network with aggregation of light neurofilament
1525 protein: a common pathway leading to motor neuron degeneration
1526 due to Charcot-Marie-Tooth disease-linked mutations in NFL and
1527 HSPB1. *Hum Mol Genet* 16(24):3103–3116
- 1528 125. Lin H, Zhai J, Schlaepfer WW (2005) RNA-binding protein is
1529 involved in aggregation of light neurofilament protein and is im-
1530 plicated in the pathogenesis of motor neuron degeneration. *Hum*
1531 *Mol Genet* 14(23):3643–3659
- 1532 126. Watson D (1991) Regional variation in the abundance of axonal
1533 cytoskeletal proteins. *J Neurosci Res* 30(1):226–231
- 1534 127. Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM (2009) CSF
1535 neurofilament protein analysis in the differential diagnosis of
1536 ALS. *J Neurol* 256(4):615–619
- 1537 128. Steinacker P, Feneberg E, Weishaupt J et al (2016) Neurofilaments
1538 in the diagnosis of motoneuron diseases: a prospective study on 455
1539 patients. *J Neurol Neurosurg Psychiatry* 87(1):12–20
- 1540 129. Tortelli R, Ruggieri M, Cortese R et al (2012) Elevated cerebro-
1541 spinal fluid neurofilament light levels in patients with amyotrophic
1542 lateral sclerosis: a possible marker of disease severity and progres-
1543 sion. *Eur J Neurol* 19(12):1561–1567
- 1544 130. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen
1545 PM (2007) Cerebrospinal fluid neurofilament light levels in amy-
1546 otrophic lateral sclerosis: impact of SOD1 genotype. *Eur J Neurol*
1547 14(12):1329–1333
- 1548 131. Tortelli R, Copetti M, Ruggieri M et al (2015) Cerebrospinal fluid
1549 neurofilament light chain levels: marker of progression to gener-
1550 alized amyotrophic lateral sclerosis. *Eur J Neurol* 22(1):215–218
- 1551 132. Poesen K, Van Damme P (2019) Diagnostic and prognostic per-
1552 formance of neurofilaments in ALS. *Front Neurol* 9:1167
- 1553 133. Menke RA, Gray E, Lu CH et al (2015) CSF neurofilament light
1554 chain reflects corticospinal tract degeneration in ALS. *Ann Clin*
1555 *Transl Neurol* 2(7):748–755
- 1556 134. Feneberg E, Oeckl P, Steinacker P et al (2018) Multicenter eval-
1557 uation of neurofilaments in early symptom onset amyotrophic lat-
1558 eral sclerosis. *Neurology* 90(1):e22–e30
- 1559 135. Gille B, De Schaepdryver M, Goossens J et al (2019) Serum
1560 neurofilament light chain levels as a marker of upper motor neuron
1561 degeneration in patients with amyotrophic lateral sclerosis.
1562 *Neuropathol Appl Neurobiol* 45(3):291–304
- 1563 136. Lu CH, Macdonald-Wallis C, Gray E et al (2015) Neurofilament
1564 light chain: a prognostic biomarker in amyotrophic lateral sclero-
1565 sis. *Neurology* 84(22):2247–2257
- 1566 137. Gaiani A, Martinelli I, Bello L et al (2017) Diagnostic and prog-
1567 nostic biomarkers in amyotrophic lateral sclerosis: neurofilament
1568 light chain levels in definite subtypes of disease. *Jama Neurol*
1569 74(5):525–532
- 1570 138. Steinacker P, Huss A, Mayer B et al (2017) Diagnostic and prog-
1571 nostic significance of neurofilament light chain NF-L, but not
1572 progranulin and S100B, in the course of amyotrophic lateral scler-
1573 osis: data from the German MND-net. *Amyotroph Lateral Scler*
1574 *Frontotemporal Degener* 18(1–2):112–119
- 1575 139. Verde F, Steinacker P, Weishaupt JH et al (2019) Neurofilament
1576 light chain in serum for the diagnosis of amyotrophic lateral scler-
1577 osis. *J Neurol Neurosurg Psychiatry* 90(2):157–164
- 1578 140. Thouvenot E, Demattei C, Lehmann S et al (2020) Serum neuro-
1579 filament light chain at time of diagnosis is an independent prog-
1580 nostic factor of survival in amyotrophic lateral sclerosis. *Eur J*
1581 *Neurol* 27(2):251–257
- 1582 141. Poesen K, De Schaepdryver M, Stubendorff B et al (2017)
1583 Neurofilament markers for ALS correlate with extent of upper
1584 and lower motor neuron disease. *Neurology* 88(24):2302–2309
- 1585 142. De Schaepdryver M, Lunetta C, Tarlarini C et al (2020)
1586 Neurofilament light chain and C reactive protein explored as pre-
1587 dictors of survival in amyotrophic lateral sclerosis. *J Neurol*
1588 *Neurosurg Psychiatry* 91(4):436–437
- 1589 143. Weydt P, Oeckl P, Huss A et al (2016) Neurofilament levels as
1590 biomarkers in asymptomatic and symptomatic familial amyotro-
1591 phic lateral sclerosis. *Ann Neurol* 79(1):152–158
- 1592 144. Benatar M, Wu J, Andersen PM, Lombardi V, Malaspina A
1593 (2018) Neurofilament light: a candidate biomarker of presymp-
1594 tomatic amyotrophic lateral sclerosis and phenoconversion. *Ann*
1595 *Neurol* 84(1):130–139
- 1596 145. Olsson B, Alberg L, Cullen NC et al (2019) NFL is a marker of
1597 treatment response in children with SMA treated with nusinersen.
1598 *J Neurol* 266(9):2129–2136
- 1599 146. Corey DR (2017) Nusinersen, an antisense oligonucleotide drug
1600 for spinal muscular atrophy. *Nat Neurosci* 20(4):497–499
- 1601 147. Wurster CD, Günther R, Steinacker P et al (2019) Neurochemical
1602 markers in CSF of adolescent and adult SMA patients undergoing
1603 nusinersen treatment. *Ther Adv Neurol Disord* 12:
1604 1756286419846058
- 1605 148. Fratta P, Nirmalanathan N, Masset L et al (2014) Correlation of
1606 clinical and molecular features in spinal bulbar muscular atrophy.
1607 *Neurology* 82(23):2077–2084
- 1608 149. Respondek G, Roeber S, Kretzschmar H et al (2013) Accuracy of
1609 the National Institute for Neurological Disorders and Stroke/Society
1610 for Progressive Supranuclear Palsy and neuroprotection and natural
1611 history in Parkinson plus syndromes criteria for the diagnosis of
1612 progressive supranuclear palsy. *Mov Disord* 28:504–509
- 1613 150. Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino
1614 G (2016) Accuracy of clinical diagnosis of Parkinson disease: a
1615 systematic review and meta-analysis. *Neurology* 86(6):566–576
- 1616 151. Rizzo G, Arcuti S, Copetti M et al (2018) Accuracy of clinical
1617 diagnosis of dementia with Lewy bodies: a systematic review and
1618 meta-analysis. *J Neurol Neurosurg Psychiatry* 89(4):358–366
- 1619 152. Miki Y, Foti SC, Asi YT et al (2019) Improving diagnostic accu-
1620 racy of multiple system atrophy: a clinicopathological study. *Brain*
1621 142(9):2813–2827

153. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM (2007) CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. *Neurobiol Aging* 28(5):742–747
154. Herbert MK, Aerts MB, Beenes M et al (2015) CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders. *Front Neurol* 6:91
155. Tsukamoto K, Matsue E, Kanasaki Y et al (2012) Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging. *Neuroradiology* 54:947–955
156. Hansson O, Janelidze S, Hall S et al (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. *Neurology* 88:930–937
157. Parnetti L, Gaetani L, Eusebi P et al (2019) CSF and blood biomarkers for Parkinson's disease. *Lancet Neurol* 18(6):573–586
158. Marques TM, van Rumund A, Oeckl P et al (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. *Neurology* 92(13):e1479–e1486
159. Oosterveld LP, Verberk IMW, Majbour NK et al (2020) CSF or serum neurofilament light added to α -synuclein panel discriminates Parkinson's from controls. *Mov Disord* 35(2):288–295
160. Ng ASL, Tan YJ, Yong ACW et al (2020) Utility of plasma neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease. *Mol Neurodegener* 15(1):33
161. Mollenhauer B, Dakna M, Liu T-Y et al (2019) Validation of serum neurofilament light chain as a biomarker of Parkinson's disease progression. *bioRxiv*. Cold Spring Harbor Laboratory; Epub:762237. <https://doi.org/10.1101/762237>
162. Lin CH, Li CH, Yang KC et al (2019) Blood NfL: a biomarker for disease severity and progression in Parkinson disease. *Neurology* 93(11):e1104–e1111
163. Rojas JC, Karydas A, Bang J et al (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. *Ann Clin Transl Neurol* 3:216–225
164. Donker Kaat L, Meeter LH, Chiu WZ et al (2018) Serum neurofilament light chain in progressive supranuclear palsy. *Parkinsonism Relat Disord* 56:98–101
165. Wilke C, Bender F, Hayer SN et al (2018) Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. *J Neurol* 265(7):1618–1624
166. Abdo WF, van de Warrenburg BP, Munneke M et al (2006) CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. *Neurology* 67:474–479
167. Li QF, Dong Y, Yang L et al (2019) Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3. *Mol Neurodegener* 14(1):39
168. Zeitberger AM, Thomas-Black G, Garcia-Moreno H et al (2018) Plasma markers of neurodegeneration are raised in Friedreich's ataxia. *Front Cell Neurosci* 12:366
169. Hayer SN, Liepelt I, Barro C et al (2020) NfL and pNfH are increased in Friedreich's ataxia. *J Neurol* 267(5):1420–1430
170. Johnson CD, Davidson BL (2010) Huntington's disease: progress toward effective disease-modifying treatments and a cure. *Hum Mol Genet* 19(R1):R98–R102
171. Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. *Nat Rev Dis Primers* 1:15005
172. Craufurd D, MacLeod R, Frontali M et al (2015) Diagnostic genetic testing for Huntington's disease. *Pract Neurol* 15(1):80–84
173. Constantinescu R, Romer M, Oakes D, Rosengren L, Kiebert K (2009) Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease. *Parkinsonism Relat Disord* 15(3):245–248
174. Niemelä V, Landtblom AM, Blennow K, Sundblom J (2017) Tau or neurofilament light-which is the more suitable biomarker for Huntington's disease? *PLoS One* 12(2):e0172762
175. Ross CA, Aylward EH, Wild EJ et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. *Nat Rev Neurol* 10(4):204–216
176. Wild EJ, Boggio R, Langbehn D et al (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. *J Clin Invest* 125(5):1979–1986
177. Byrne LM, Rodrigues FB, Blennow K et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. *Lancet Neurol* 16(8):601–609
178. Rodrigues FB, Byrne LM, Wild EJ (2018) Biofluid biomarkers in Huntington's disease. *Methods Mol Biol* 1780:329–396
179. Johnson EB, Byrne LM, Gregory S et al (2018) Neurofilament light protein in blood predicts regional atrophy in Huntington disease. *Neurology* 90(8):e717–e723
180. Byrne LM, Rodrigues FB, Johnson EB et al (2018) Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. *Sci Transl Med* 10(458):eaat7108
181. Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M (2020) Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. *Lancet Infect Dis* 20(1):e2–e10
182. Parchi P, Giese A, Capellari S et al (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. *Ann Neurol* 46(2):224–233
183. Zerr I, Kallenberg K, Summers DM et al (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. *Brain* 132:2659–2668
184. Zanusso G, Fiorini M, Ferrari S et al (2011) Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease. *Int J Mol Sci* 12: 6281–6292
185. Steinacker P, Blennow K, Halbgebauer S et al (2016) Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. *Sci Rep* 6:38737
186. Zerr I, Schmitz M, Karch A et al (2018) Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. *Alzheimers Dement* 14(6):751–763
187. Abu-Rumeileh S, Capellari S, Stanzani-Maserati M et al (2018) The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. *Alzheimers Res Ther* 10(1):3
188. Thompson AGB, Luk C, Heslegrave AJ et al (2018) Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. *J Neurol Neurosurg Psychiatry* 89(9):955–961
189. Kovacs GG, Andreasson U, Liman V et al (2017) Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. *Eur J Neurol* 24(11):1326–1e77
190. Staffaroni AM, Kramer AO, Casey M et al (2019) Association of blood and cerebrospinal fluid tau level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease. *JAMA Neurol* 76(8):969–977
191. Ladogana A, Kovacs GG (2018) Genetic Creutzfeldt-Jakob disease. *Handb Clin Neurol* 153:219–242
192. Kim MO, Takada LT, Wong K, Forner SA, Geschwind MD (2018) Genetic PrP prion diseases. *Cold Spring Harb Perspect Biol* 10(5):a033134
193. Vallabh SM, Minikel EV, Schreiber SL, Lander ES (2020) Towards a treatment for genetic prion disease: trials and biomarkers. *Lancet Neurol* 19(4):361–368

1753 194. Baldacci F, Lista S, Vergallo A, Palermo G, Giorgi FS, Hampel H 1769
1754 (2019) A frontline defense against neurodegenerative diseases: the 1770
1755 development of early disease detection methods. *Expert Rev Mol* 1771
1756 *Diagn* 19(7):559–563 1772
1757 195. Ashton NJ, Hye A, Rajkumar AP et al (2020) An update on blood- 1773
1758 based biomarkers for non-Alzheimer neurodegenerative disorders. 1774
1759 *Nat Rev Neurol* 16(5):265–284 1775
1760 196. Hampel H, Lista S (2013) Use of biomarkers and imaging to 1776
1761 assess pathophysiology, mechanisms of action and target engage- 1777
1762 ment. *J Nutr Health Aging* 17(1):54–63
1763 197. Hampel H, O’Bryant SE, Castrillo JI et al (2016) Precision med-
1764 icine - the golden gate for detection, treatment and prevention of
1765 Alzheimer’s disease. *J Prev Alzheimers Dis* 3(4):243–259
1766 198. Hampel H, Toschi N, Babiloni C et al (2018) Revolution of
1767 Alzheimer precision neurology. *Passageway of systems biology*
1768 and neurophysiology. *J Alzheimers Dis* 64(s1):S47–S105
1780

199. Hampel H, O’Bryant SE, Durrleman S et al (2017) A precision 1769
medicine initiative for Alzheimer’s disease: the road ahead to 1770
biomarker-guided integrative disease modeling. *Climacteric* 1771
20(2):107–118 1772
200. Hampel H, Vergallo A, Aguilar LF et al (2018) Precision pharma- 1773
cology for Alzheimer’s disease. *Pharmacol Res* 130:331–365 1774
201. Hampel H, Vergallo A, Perry G, Lista S, Alzheimer Precision 1775
Medicine Initiative (APMI) (2019) The Alzheimer Precision 1776
Medicine Initiative. *J Alzheimers Dis* 68(1):1–24 1777

Publisher’s Note Springer Nature remains neutral with regard to jurisdic- 1778
tional claims in published maps and institutional affiliations. 1779

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES.

- Q1. Please check if the affiliations are captured and presented correctly.
- Q2. Please check if the section headings are assigned to appropriate levels.
- Q3. Please check the provided expanded form for the abbreviation “MMSE” if correct.
- Q4. Please check the word “diseases” inserted after the word “neurodegenerative,” which can be found in the sentence starting “Finally, serum NFL levels were reported relatively lower,” for completeness if correct.
- Q5. References [19, 174], [22, 186], [200, 203] based on original manuscript we received were identical. Hence, the latter was deleted and reference list and citations were adjusted. Please check if appropriate.
- Q6. Please provide complete bibliographic details of this reference.